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ABSTRACT
QUANTIFICATION OF MITOCHONDRIAL MEMBRANE POTENTIAL
IN THE ISOLATED RAT LUNG USING R6G

Anthony Cammarata, B.S.
Marquette University, 2019
Mitochondrial membrane potential (Δm) plays a key role in vital mitochondrial
functions, and its dissipation is a hallmark of mitochondrial dysfunction in various cell
types. The objective of this study was to develop an experimental and computational
approach for estimating Δm in intact rat lungs using the lipophilic fluorescent cationic
dye rhodamine 6G (R6G).
Rat lungs were isolated and connected to a ventilation-perfusion system. The
experimental Protocol consisted of three single-pass phases: loading, wash, and
uncoupling, in which the lungs were perfused with R6G-containing perfusate, fresh R6Gfree perfusate, or R6G-free perfusate containing the mitochondrial uncoupler FCCP,
respectively. This Protocol was carried out with or without lung perfusate containing
verapamil, an inhibitor of the multi-drug efflux pump P-glycoprotein.
Results show that the addition of FCCP resulted in an increase in R6G venous
effluent concentration, and that this increase was larger in the presence of verapamil than
in its absence. A physiologically based pharmacokinetic (PBPK) model for the
pulmonary disposition of R6G was developed and used for quantitative interpretation of
the kinetic data, including estimating Δm. The estimated value of Δm (-139 ± 21 (SD)
mV and -128 ± 14 mV without and with verapamil, respectively) is consistent with that
estimated previously in cultured pulmonary endothelial cells. These results demonstrate
the utility of the proposed approach for quantifying Δm in intact functioning lungs.
This approach has potential to provide quantitative assessment of the effect of
injurious conditions on lung mitochondrial function, and to evaluate the impact of
therapies that target mitochondria.
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CHAPTER 1: INTRODUCTION, BACKGROUND, AND OBJECTIVE
1.1 Clinical Motivation
Mitochondria are commonly known as the powerhouse of the cell. For pulmonary
endothelial cells, mitochondria produce approximately 80-85% of ATP needed for
cellular functions (Bongard et al., 2013; Fisher AB et al., 1984). Mitochondria are also
implicated in other important cellular functions, including apoptosis, calcium regulation,
nitric oxide signaling, and are a primary source of reactive oxygen species (ROS) under
physiological and pathophysiological conditions (Carraway et al., 2008; Sepehr et al.,
2013; Murphy et al., 2009; Bongard et al., 2013; Gan et al., 2011). Mitochondrial
membrane potential (Δm) is a major component of the mitochondrial electrochemical
transmembrane potential (proton motive force), which plays a key role in vital
mitochondrial bioenergetics, metabolic, and signaling functions (Gan et al., 2011;
Duchen et al., 2003). In addition, mitochondrial dysfunction has been implicated in the
pathogenesis of acute and chronic lung diseases (Audi et al., 2017; Fu et al., 2017; Ten et
al., 2019; Ryter et al., 2018; Piantadosi et al., 2017; Audi et al., 2005; Sepehr et al.,
2013). Thus, the ability to quantify Δm in an intact functioning lung is essential to
further the understanding of the role of mitochondrial dysfunction in the pathogenesis of
lung injury and diseases, and to assess the efficacy of potential therapies that target the
mitochondria.
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Figure 1.1: Mitochondrial Dysfunction. This schematic shows how a decrease in
mitochondrial membrane potential due to mitochondrial structural damage causes a
decrease in ATP production and an increase in ROS production (Taken from Morris et
al., 2015 with permission).

1.2 Mitochondrial Membrane Potential: Electrochemical Gradient, ATP Production
via Oxidative Phosphorylation
For lung tissue, glucose is by far the most oxidizable substrate under
physiological conditions (Bonora et al., 2012). The development of Δm and the synthesis
of most mitochondrial ATP in the lung tissue start with the cellular uptake of glucose,
followed by glycolysis and uptake of pyruvate into the citric acid or tricarboxylic acid
(TCA) cycle, and ends with oxidative phosphorylation. During glycolysis, glucose is
converted into two ATP, two NADH, and two pyruvate molecules, through a series of
chemical reactions. The two pyruvate molecules then enter the TCA cycle where they are
converted into two CO2 molecules, two ATP molecules, three NADH molecules, and one
FADH2 molecule. Lastly the FADH2 and NADH molecules are reduced to NAD+ and
FAD to provide energy for the electron transport chain (ETC) in the form of electrons.
The electrons that are produced create an electrochemical gradient. The transfer of
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electrons in the ETC (complexes I-IV) makes it possible for protons to be pumped (at
complexes I, III, and IV) against their concentration gradient, across the inner
mitochondrial membrane, and into the mitochondrial intermembrane space. Hence,
generating a proton gradient and furthermore generating a membrane potential across the
inner mitochondrial membrane. The energy that is generated via the proton motive force
(proton gradient and membrane potential) then drives the formation of 34 ATP from ADP
at complex V. This process accounts for ~80-85% of ATP production in lung tissue. It
should be noted that the total molecules of ATP created per glucose molecule is
approximately 38. Therefore, a change in Δm is indicative of a change in lung tissue
bioenergetics and mitochondrial function (Perry et al., 2011; Bonora et al., 2012).

Figure 1.2: Cellular Bioenergetics. Schematic of the three main cellular processes
(glycolysis, TCA cycle, and oxidative phosphorylation) that are involved in the
conversion of glucose to ATP (Taken from Cunningham et al., 2004 with permission).
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Figure 1.3: Mitochondrial ETC and ATP Synthesis Schematic Representation. The
four complexes of the ETC are shown as well as ATP synthase. The ETC is important in
regulating membrane potential (Taken from Nussbaum et al., 2005 with permission).
Dissipation of Δm is a hallmark of mitochondrial dysfunction observed in
various cell types, including pulmonary endothelial cells exposed to oxidative stress (Gan
et al., 2011; Ma et al., 2018; Merker et al., 2009; Ruchko et al., 2005). Regulation of Δm
is very important, not only for ATP production, but also for the transport of metabolites
and ions in and out of the cells. Δm also has a large influence on the importing of
precursors for enzymes and mitochondrial protein synthesis (Chen et al., 1988).
Therefore, conditions that alter Δm could lead to mitochondrial dysfunction. Hence, the
ability to quantify Δm is critical for understanding the pathogenesis of lung diseases for
which mitochondrial dysfunction is a key factor. It is also important for the evaluation of
the efficacy of novel therapies that target mitochondrial function.
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1.3 Methods for Measuring Mitochondrial Membrane Potential
Fluorescent lipophilic cations such as rhodamine dyes have been used for
monitoring Δm, predominantly in reduced systems, including cultured cells and isolated
mitochondria (Gan et al., 2011; Fu et al., 2017; Farkas et al., 1989; Perry et al., 2011;
Aiuchi et al., 1982; Johnson et al., 1981; Scaduto et al., 1999). For most studies, this
involved measurement of the intensity of fluorescent dyes within cultured cells or
isolated mitochondria. Such measurements are confounded by the propensity of the dyes
to undergo self-aggregation and quenching due to accumulation in mitochondria and
cytosol (Gan et al., 2011).
A study by Perry et al. included the development of a guide for using cationic
probes for assessing Δm (Perry et al., 2011). The study provides an overview of cationic
dyes that have been used to measure membrane potential, including TMRM, TMRE, and
R123. The study also provides a step by step description on how cationic probes can be
used properly to assess Δm.
Previous studies have demonstrated the utility of cationic rhodamine dyes,
including rhodamine 6G (R6G), to probe Δm mostly in isolated mitochondria and
cultured cells (Gan et al., 2011; Scaduto et el., 1999; Johnson et al., 1981; Baracca et al.,
2003; Farkas et al., 1989; Mandalà et al., 1999; Aiuchi et al., 1982; Ehrenberg et al.,
1988; Gear et l., 1974; Solaini et al., 2007). Mandalà et al. used R6G as a probe for
plasma membrane potential in cultured bovine aortic endothelial cells (Mandalà et al.,
1999). They reported a linear relationship between the fluorescence intensity (F.I.) and
the plasma membrane potential. The value of F.I. dropped following the addition of an
inflammatory mediator and mitochondrial uncoupler (bradykinin), an ionophore
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(nigericin), and/or the sodium-potassium ion pump inhibitor ouabain to the medium
surrounding the cells. However, the addition of mitochondrial inhibitors (myxothiazol
and oligomycin) to the medium did not affect F.I., which may suggest that R6G is not
sensitive enough to changes in Δm (Mandala et al., 1999). However, other studies have
shown that R6G is a mitochondrial specific dye and therefore can provide a measure of
Δm (Johnson et al., 1981; Farkas et al., 1989). For instance, Johnson et al. performed a
study in which they monitored the relative Δm in living cells using cationic dyes
including Rhodamine 123 (R123) and R6G. The results indicate that the fluorescence
intensities associated with mitochondria were reflections of Δm (Johnson et al., 1981).
R6G was also used to evaluate Δm in rat brain synaptosomes (Aiuchi et al., 1982). They
demonstrated that R6G emission signal increased when depolarizing agents were added
to the synaptosome suspension medium. In addition, the authors developed a modified
Nernst equation that allows for the conversion of changes in R6G emission signal to
membrane potential in mV (Aiuchi et al., 1982). Ehrenberg et al. also demonstrated the
utility of cationic dyes, including R6G, to probe membrane potential in various types of
cultured cells (Ehrenberg et al., 1988). These studies clearly demonstrated the utility of
R6G probing Δm in isolated mitochondrial and cultured cells.
Huang et al. performed a study in which they developed a model that allowed
them to better understand the relationship between Δm and measured fluorescence using
the cationic dye R123 (Huang et al., 2007). They performed experiments in isolated
cardiac mitochondria, and developed a computational model for quantitative
interpretation of the resulting kinetic data. The model they used incorporated dye flux
across a membrane as well as dye self-quenching. This was then added to a model of
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mitochondrial electrophysiology which was used to estimate various parameters from the
measured kinetic fluorescence data, including Δm.
Gan et al. developed an experimental and computational approach for estimating
mitochondrial and plasma (cellular) membrane potentials in cultured pulmonary arterial
endothelial cells based on the extracellular disposition of the rhodamine dye tetramethyl
rhodamine ethyl ester perchlorate (TMRE) and rhodamine 123 (R123) following its
addition to the surrounding medium (Gan et al., 2011). Unlike other studies with cultured
cells, Gan et al. evaluated the cellular uptake of each dye by measuring changes in its
concentration in the surrounding medium instead of the concentration in cells (Gan et al.,
2011). For quantitative interpretation of the measured kinetic data, they developed a
computational model that accounted for the dominant processes that determine the uptake
of each dye, including plasma and mitochondrial membrane potentials and the multi-drug
efflux pump P-glycoprotein (Pgp) for which TMRE and R123 are substrates (Gan et al.,
2011). Pgp pumps rhodamine dyes from the cytoplasm back into the surrounding
medium. The objective of the present study was to develop a similar experimental and
computational approach for estimating Δm in isolated perfused rat lungs using the
lipophilic fluorescent cationic dye rhodamine 6G (R6G).
Our choice of R6G for this study was motivated in part by the work of Roerig et
al. who demonstrated significant R6G uptake and retention in isolated perfused rabbit
lungs (Roerig et al., 2004), and by R6G’s high permeability in cell membranes of several
types of cells, including pulmonary endothelial cells (Mandala et al., 1999).
Scaduto et al. attempted to probe Δm in the intact heart by monitoring the surface
emission fluorescent of Tetramethylrhodamine Methyl Ester Perchlorate (TMRM)
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(Scaduto et al., 1999). Recirculated TMRM in perfusate was taken up and retained in the
heart tissue. However, the results with mitochondrial uncouplers were difficult to
interpret in part because of alteration in the fluorescent properties of TMRM in heart
tissue due to the accumulation of TMRM in mitochondria. The experimental and
computational approach described in this thesis overcomes this limitation by estimating
the lung uptake and accumulation of R6G from the lung inlet and outlet R6G
concentrations on passage through the pulmonary circulation instead of from lung surface
measurements, and by using a computational PBPK model to account for the dominant,
various vascular and tissue processes that determine the lung uptake and accumulation of
R6G, including Δm.
1.4 Objective and Specific Aims:
Previous studies have quantified Δm predominately in isolated lung tissue
mitochondria and to lesser extent in cultured lung cells using various cationic dyes,
including rhodamine dyes (Gan et al., 2011; Scaduto et al., 1999; Perry et al., 2011; Chen
et al., 1988; Johnson et al., 1981; Davis et al., 1985; Baracca et al., 2003; Huang et al.,
2007; Mandala et al., 1999; Aiuchi et al., 1982). Studies using these reduced systems are
useful and provide important information which allows for the application of several
tools of cell biology that are not applicable at the organ level. However, they cannot
reproduce the multicellular environment in an intact functioning lung under physiological
and pathophysiological conditions. Therefore, an approach for quantifying Δm in an
intact functioning lung is needed. Thus, the objective of this thesis was to develop an
experimental and computational approach for estimating Δm in isolated perfused rat
lungs using the cationic fluorescent dye R6G. Thus, the specific aims of the thesis are to:
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Aim # 1: evaluate the pharmacokinetics of R6G uptake in isolated perfused rat
lungs. For this aim, experiments were carried out under different experimental conditions
to identify the dominant processes that determine the uptake and retention of R6G on
passage through the pulmonary circulation, and the sensitivity of R6G lung uptake to
changes in Δm.
Aim # 2: Develop a physiologically-based pharmacokinetic (PBPK) model for
mechanistic and quantitative interpretation of the R6G spectroscopy kinetic data
during passage through the rat pulmonary circulation. The lung uptake and retention of
R6G on passage through the pulmonary circulation is the net result of multiple tissue and
vascular processes, and hence estimating the mitochondrial membrane potential Δm or a
change in Δm from the measured kinetic data is not straight forward. Thus, for this aim
we developed a PBPK computational modeling for estimating parameters descriptive of
those processes, including Δm, from the differences between lung inlet and outlet
perfusate R6G concentrations under different experimental conditions.
The results of the present study demonstrate the utility of the described
experimental and computational approach for quantifying Δm in isolated perfused lungs.

10

CHAPTER 2: EXPERIMENTAL METHODS
2.1 Materials
Rhodamine-6G (R6G), verapamil hydrochloride, Carbonyl cyanide 4(trifluoromethoxy) phenylhydrazone (FCCP), and all other reagents that are used in
experiments were purchased from Sigma-Aldrich (St. Louis, MO).
2.2 Isolated, Perfused Rat Lung Preparation
Animal Protocols described below were approved by the Institutional Animal
Care and Use Committees of the Veterans Affairs Medical Center and Marquette
University (Milwaukee, WI).
Adult male Sprague-Dawley rats (348 ± 3 g (SE), n = 59) were used for this
study. Each rat was anesthetized with sodium pentobarbital (40-50 mg/kg
intraperitoneal). The trachea was surgically isolated and cannulated, the chest opened and
heparin (0.7 IU/g body wt.) injected into the right ventricle as previously described (Audi
et al., 2018). The pulmonary artery and the pulmonary venous outflow were accessed via
cannulas, then the heart/lungs were removed and connected to a ventilation-perfusion
system.
The Krebs-Ringer bicarbonate perfusate contained (in mM) 4.7 KCl, 2.51 CaCl2,
1.19 MgSO4, 2.5 KH2PO4, 118 NaCl, 25 NaHCO3, and 5.5 glucose. The perfusate also
contained 0.5% to 3% bovine serum albumin (BSA) plus 2.5% to 0% Ficoll to maintain
consistent oncotic pressure. The perfusion system was primed with the perfusate
maintained at 37oC and equilibrated with 15% O2, 6% CO2, balance N2 gas mixture
resulting in perfusate PO2, PCO2 and pH of ~105 Torr, 40 Torr, and 7.4, respectively.
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The lung was ventilated (40 breaths/min) with the above gas mixture with end-inspiratory
and end-expiratory pressures of ~ 6 and 3 mmHg, respectively. The pulmonary artery and
airway pressures were referenced to atmospheric pressure at the level of the left atrium
and monitored continuously during the experiments. Perfusate was pumped (5 to 20
ml/min) through the lung until it was evenly blanched and venous effluent was clear of
visible blood before switching from single pass to recirculation mode.

Figure 2.1: Schematic of the Ventilation-Perfusion system used for IPL experiments.

2.3 Hyperoxia treatment:
Rat exposure to high oxygen environment (hyperoxia is a well-established animal
model of clinical acute lung injury(Audi et al., 2005; Audi et al., 2016). Rats were placed
in a sealed, temperature controlled, acrylic chamber 59 L chamber (33.0 × 58.3 × 30.5
cm) and exposed to >95% oxygen (n = 2) for 48 hours. Within the chamber, carbon
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dioxide levels were maintained at <0.5%, and temperature was maintained at 20-22°C.
The rats were exposed to a 12:12 hours light-dark cycle. The O2 and CO2 levels were
monitored to ensure the desired O2 concentration was achieved. This Protocol has been
approved by the Institutional Animal Care and Use Committees of the Veterans Affairs
Medical Center and Marquette University (Milwaukee, WI).
2.4 Optical Imaging Systems
The RatioMaster fluorescence imaging system (Photon Technology International,
HORIBA Scientific) was used to measure the R6G fluorescence (Figure 2.2). It uses a
xenon bulb as the light source and is operated and controlled using custom software
(FelixGX-4.3.2010) which is run using a windows operating system. For R6G, the
monochromator was set to an excitation wavelength of 525 nm. The emission filter used
(Chroma Technology Corporation, Bellows Falls, Vermont part # AT565/30m) has a
wavelength of 565 ± 15 nm.

Figure 2.2: PTI System used to gather experimental data
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Table 2.1: Inhibitors and Uncouplers and their Target Sites.
Effects of Inhibitors and Uncouplers
P-trifluoromethoxy
- Protonophore: uncouples the mitochondrial membrane potential by
increasing the membrane’s permeability to protons.
carbonyl-cyanide phenylLow concentrations depolarize the mitochondrial membrane while
hydrazone (FCCP)
high concentrations may also depolarize the plasma membrane
(Perry et al., 2011)
Verapamil hydrochloride

- Inhibitor of the plasma membrane Pgp pump.

2.5 Experimental Protocols
Protocol 1: Effect of R6G input concentration, pump flow, and perfusate % BSA on R6G
extraction on passage through the lungs.
For this Protocol, the objective was to assess the impact of R6G infused
concentration, perfusate flow, perfusate % BSA, and connecting tubing from the
perfusate reservoir to the lungs on R6G uptake on its passage through the pulmonary
circulation.
For the first set of experiments (n = 7), the perfusate included 0.5% BSA and
2.5% Ficoll. Once the lungs were clear of blood, the pump was stopped, and the reservoir
emptied and then refilled with 120 ml of perfusate. Two 1 ml reservoir samples were
collected before and after the addition of R6G for a final concentration of 0.25 M.
Those samples were used to determine the background signal and the actual R6G
concentration in the reservoir. During the 10 minute lung perfusion (single pass mode)
with the R6G-containing perfusate, two 1-ml lung venous effluent samples were collected
every 20 seconds for the first 5 minutes and every minute for the last 5 minutes, with the
first sample collected at time 40 seconds, where t = 0 seconds was the start of the loading
phase. Based on the volume (~ 4 ml) of the system (lung + tubing) and flow, one would
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expect no R6G signal in the venous effluent samples collected prior to 40 seconds.
Samples were then centrifuged for 1 min (13,000 g, 4°C) to remove any cellular
components and debris. The sample supernatant was then transferred into a plastic
cuvette and its 565 nm emission signal (525 nm excitation) was measured using a
RatioMaster fluorescence system (Photon Technology International, HORIBA Scientific,
NJ) (Audi et al., 2018). The emission filter was centered at 565 nm (ET565/30M,
Chroma, VT) with a bandwidth of 30 nm. R6G optical density was determined and
converted to concentration using a standard curve. The lung R6G extraction ratio (ER), a
measure of the fraction of the input extracted on passage through the lungs, was
determined using the following equation

ER = 1 −

[Cv ]
[Cin ]

(2.1)

where [Cv] is the R6G venous effluent concentration and [Cin] is the infused R6G
concentration (0.25 M).
For some experiments (n = 3), the above Protocol was repeated with no lungs
attached to the ventilation-perfusion system to assess the impact of the tubing connecting
the reservoir to the lungs on the concentration of R6G in the venous effluent.
Based on results from the above experiments (see Results section), it was
determined that the R6G concentration in the venous effluent approached steady state at
~6 min at a pump flow of 10 ml/min. Thus, for subsequent experiments under Protocol 1,
venous effluent was collected only 6 min after the start of the pump for a flow of 10
ml/min, and only 3 min and 12 min after the start of the pump for flows of 5 ml/min and
20 ml/min, respectively.

15
Using the above Protocol with flow of 10 ml/min, we assessed the impact of R6G
input (reservoir) concentration (0.125, 0.5, or 1.25 M) on R6G ER on passage through
the pulmonary circulation. For 0.5 M and 1.25 M, venous effluent samples were first
diluted with perfusate before measuring the emission signal to keep the intensity within
the dynamic range of the fluorescence measuring system. In addition, we assessed the
impact of changing perfusate % BSA (1%, 2%, or 3%) on R6G ER at 10 ml/min. For
perfusate with BSA concentration of 1, 2 or 3%, the Ficoll concentration was 2%, 1% and
0%, respectively, to maintain constant oncotic pressure.
Using the above Protocol with perfusate of 0.5 % BSA and R6G reservoir
concentration of 0.25 M, we assessed the impact of pump flow (5 ml/min or 10 ml/min)
on R6G ER on passage through the pulmonary circulation.
At the end of the above Protocol, the lungs were removed from the system and
their wet weight was measured. The lungs were then dried, and the dry weight was
measured.
Protocol 2: Effect of treating isolated perfused lungs with verapamil and/or FCCP on
R6G venous effluent concentration.
Based on results from Protocol 1 (see Results section), the following experimental
conditions were used for Protocol 2: perfusate with 0.5% BSA +2.5% Ficoll, 10 ml/min
pump flow, and 0.25 M R6G reservoir concentration. These conditions result in lung
steady-state ER of ~ 0.5, halfway within the dynamic range (0 to 1) of ER.
Protocol 2 consisted of three single-pass perfusion phases: The loading phase in
which the lungs were perfused with R6G-containing perfusate, the wash phase in which
the lungs were perfused with fresh perfusate with no R6G, and the uncoupled phase in
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which the lungs were perfused with perfusate containing the uncoupler FCCP and no
R6G. Once the lungs were visually clear of blood, the flow was stopped to empty the
perfusate in the reservoir and refilled with 120 ml of fresh perfusate. Before mixing the
perfusate with the R6G, two 1-ml samples were collected to provide background signal
for the loading phase. R6G stock (41.8 M) was then added to the perfusate in the
reservoir for a final concentration of ~0.25 M. Two 1-ml samples were then collected
from the reservoir to provide a measure of actual R6G lung input concentration for the
loading phase. The remaining perfusate was used to perfuse the lungs during the 10
minute loading phase. During this phase, two 1-ml lung venous effluent samples were
collected every 20 seconds for the first 5 minutes and every minute for the last 5 minutes,
with the first sample collected 40 seconds after the start of the loading phase.
At the end of the loading phase, the pump was stopped, and the reservoir quickly
emptied and then refilled with R6G-free perfusate that was used to perfuse the lungs
during the 3-minute wash phase. Prior to restarting the pump for the wash phase, two
1-ml samples were collected from the reservoir and used as background samples for the
wash phase. During the wash phase, two 1-ml venous effluent samples were collected
every minute.
At the end of the wash phase, the pump was stopped again, and the reservoir
emptied and then refilled with 75 ml of R6G-free perfusate containing the uncoupler
FCCP at a concentration of 67 M. This concentration is high enough to ensure maximal
dissipation of mitochondrial membrane potential (Zhao et al., 2013; Huang et al., 2018).
This FCCP-containing perfusate was used to perfuse the lungs during the 7-min
uncoupling phase. Prior to starting the pump for the uncoupling phase, two 1-ml samples
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were collected to provide background signal. Venous effluent samples were collected
every 20 seconds for the first two minutes and then every minute for the last 5 minutes
during this phase.
All samples from the three phases of Protocol 2 were centrifuged for 1 min
(13,000 g, 4°C) to remove any cellular components and debris. The sample supernatant
was then transferred into a plastic cuvette and its 565 nm emission signal (525 nm
excitation) was measured (Audi et al., 2018). The R6G emission signal was determined
and converted to concentration using a standard curve (see Appendix D).

Figure 2.3: Cuvette and Fiber Optic Cable Holder

At the end of Protocol 2, the lungs were removed from the system. Their wet
weight was measured, the lungs were dried, and then their dry weight was measured.
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2.5.1 Effects of Pgp inhibitors on R6G lung uptake
For a separate group of lungs, the above Protocol was carried out following the
inhibition of the Pgp pump that pumps R6G out of the lungs. To inhibit the Pgp pump,
Protocol 2 was modified as follows. Prior to the loading phase, perfusate containing
verapamil (0.1 mM) Audi et al., 2018) was recirculated through the lungs for 3 minutes at
10 ml/min after which time the flow was stopped, and the reservoir emptied and refilled
with perfusate for the loading phase. In addition, perfusate used for all three phases
included verapamil (0.1 mM). This concentration is high enough to ensure maximal
inhibition of Pgp (Audi et al., 2018; Roerig et al., 2004).
2.5.2 Effects of the uncoupler vehicle, DMSO
FCCP is soluble in dimethyl sulfoxide (DMSO). At high concentrations, DMSO
is known to have negative effects (Yuan et al., 2014). Therefore, it was important to
know if the concentration DMSO used had any effect on the lung uptake or washout of
R6G. To determine the impact of DMSO alone on the lung uptake of R6G, the Protocol
was repeated with just DMSO (0.05 % of the perfusate volume) added to the perfusate
during the uncoupling phase of Protocol 2.
2.5.3 Standard Curve
For each experimental day, a standard curve was obtained as described below and
used to convert R6G emission signal in collected samples to R6G concentration. Six
tubes containing perfusate with known concentrations of R6G (0.5 M, 0.25 M, 0.125
M, 0.0625 M, and 0.03125 M) were prepared. For each tube, a 2-ml sample was
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collected then processed the same way as the samples collected from the lung’s venous
effluent. Thus, each sample was centrifuged for 1 min (13,000 g, 4°C), after which its
565 nm emission signal was measured. The standard curve was repeated with either
verapamil, FCCP, or GF-120918 added to the samples prior to the addition of R6G to
determine if the inhibitor/uncoupler and/or its vehicle interfered with the R6G emission
signal.
2.6 Effect of rat exposure to hyperoxia on R6G lung uptake:
Protocol 2 was repeated on 2 lungs from rats exposed to >95% O2 for 48 hours.
2.7 Statistical Analysis
Statistical evaluation of data was carried out using SigmaPlot version 12.0 (Systat
Software Inc., San Jose, CA). Values from different groups were compared using
unpaired t-tests. The level of statistical significance was set at p < 0.05. Values are mean
± SE unless otherwise indicated.
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CHAPTER 3: EXPERIMENTAL RESULTS
3.1 Rats body weights, lungs wet and dry weights, lungs wet/dry weight ratios, and
pulmonary artery pressures:
Table 3.1 shows no significant differences between the body weights, lung wet
and dry weights, the wet/dry ratios, and the pulmonary artery pressures of the rats used
for Protocols 1 and 2.
Table 3.1: Body weight, lung wet and dry weight, and wet/dry weight ratio, and
pulmonary artery pressure for flow rate of 10ml/min.

Protocol #

Body weight
(g)

Protocol 1

345.0 ± 2.8
(n = 46)

Protocol 2
365.77 ± 7.8
(normoxic
(n = 13)
rats)
Protocol 2
325.5 ± 7.42
(hyperoxic
(n = 2)
rats)
Values are mean ± SE.

Lung dry
weight (g)

Wet/dry
weight ratio

Pulmonary
artery
pressure
(mmHg)

1.21 ± 0.02 0.23 ± 0.02
(n = 46)
(n = 46)

5.49 ± 0.10
(n = 46)

7.51 ± 0.15
(n = 46)

1.30 ± 0.03 0.24 ± 0.01
(n = 13)
(n = 13)

5.35 ± 0.06
(n = 13)

6.45 ± 0.24
(n = 13)

1.36 ± 0.07 0.23 ± 0.01
(n = 2)
(n = 2)

5.85 ± 0.004
(n = 2)

5.25 ± 0.88
(n = 2)

Lung wet
weight (g)

3.2 Rhodamine-6G (R6G) standard curve for experiments:
Figure 3.1 shows example of the standard curves used to convert R6G emission
fluorescent signal to R6G concentration. Neither FCCP (67 M) nor verapamil (100 M)
had a significant effect on R6G standard curves.
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Figure 3.1: Standard curve for R6G. Perfusate BSA concentration was 0.5%. Values are

mean ± SE (n = 7).
3.3 Protocol 1: Factors that determine the lung uptake of R6G on passage through
the isolated perfused lung
Several factors determine the lung uptake of R6G, including perfusate protein
concentration (% bovine serum albumin, or % BSA) and blood flow rate. Figure 3.2
shows R6G ER after 6 min of perfusing lungs with 0.5% BSA perfusate containing
0.125, 0.25, 0.5, or 1.25 M R6G at flow of 10 ml/min. These results show that for this
concentration range, the lung ER is constant (dose-independent) consistent with firstorder kinetics for the various vascular and cellular processes that contribute to the lung
uptake of R6G.

No significant difference between ER at 0.125 and other [ ]
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ER at 6 min
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Figure 3.2: R6G lung extraction ratio (ER) after 6 min of perfusion (single pass) as a
function of R6G input (reservoir) concentration. Pump flow = 10 ml/min, and perfusate
BSA concentration was 0.5%. Values are mean ± SE (n = 6, 7, 4 and 7 for R6G
concentrations of 0.125, 0.25, 0.5, and 1.25 M, respectively).

Figure 3.3 shows R6G ER after 6 minutes of lung perfusion (10 ml/min) with
perfusate containing R6G (0.25 M) and 0.5%, 1%, 2%, or 3% BSA. The results show
that ER decreased as the % BSA in perfusate increased, consistent with a decrease in the
fraction of R6G that is available for lung uptake.
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Figure 3.3: R6G lung extraction ratio (ER, solid bars) after 6 min of perfusion (single
pass) as a function of perfusate %BSA. Pump flow = 10 ml/min. Values are mean ± SE
(n = 10, 3, 3 and 4 for perfusate BSA of 0.5, 1.0, 2.0, and 3.0%, respectively.
*
significantly different from 0.5% BSA (P < 0.05, unpaired t-test), &significantly
different from 1.0% (P < 0.05), and # significantly different from 2.0% (P < 0.05).

Figure 3.4 shows that increasing pump flow (from 5 to 20 ml/min) decreased R6G
ER, consistent with a decrease in the time available for R6G uptake. The ER was
determined at times of 12 min, 6 min, and 3 min following the start of lung perfusion
with R6G-contaning perfusate at flows of 5, 10, and 20 ml/min, respectively.
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Figure 3.4: R6G lung extraction ratio (ER, solid bars) after 12 min, 6 min, and 3 min of
perfusion (single pass) with pump flow set at 5, 10, or 20 ml/min, respectively. Values
are mean ± SE (n = 4, 10, and 6 for flow of 5, 10, and 20 ml/min, respectively.
*
significantly different from ER at flow of 10 ml/min (P < 0.05, unpaired t-test).
Based on the results in Figures 3.2 – 3.4, we chose the following experiments
conditions for Protocol 2: perfusate with 0.5% BSA (and 2.5% Ficoll) and flow rate of 10
ml/min. These conditions result in lung steady state ER of ~ 0.5, halfway within the range
(0 to 1) of ER.
Figure 3.5A shows R6G (0.25 M) ER on passage through the pulmonary
circulation at pump flow of 10 ml/min and perfusate containing 0.5% BSA. The results
show that ER approaches a steady-state value around 6 min (ER = 0.482 ± 0.013 (SE))
after the start of the perfusion of the lungs with R6G-containing perfusate. Thus at 6 min,
~48% of the infused R6G was extracted or taken up on a single pass through the lungs.

25
The experimental Protocol for Figure 3.5A was repeated with the lungs removed
from the perfusion system. The results in Figure 3.5B show that ER at steady state is not
significantly different from zero. Thus, perfusion system tubing is not contributing to
R6G ER on passage through the pulmonary circulation.

Figure 3.5: Panel A: R6G lung extraction ratio (ER) as a function of sampling time on
passage through the pulmonary circulation. R6G reservoir concentration was 0.25 M,
pump flow = 10 ml/min, and perfusate BSA concentration was 0.5%. Panel B: R6G
tubing extraction ratio (ER) as a function of sampling time. R6G reservoir concentration
was 0.25 M, pump flow = 10 ml/min, tubing volume = 4 ml, and perfusate BSA
concentration was 0.5%. Values are mean ± SE (n = 7, 3 for panels A and B,
respectively).
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3.4 Lung venous effluent R6G concentrations during the three phases of Protocol 2:
For each sample at a given sampling time, the measured intensity was determined
as the average of the intensities acquired over a period of 5 seconds. For each of the three
phases of the Protocol 2 experiments, the intensity of background samples was subtracted
from the intensities of all subsequent samples. The slope of the standard curve for each
day of experiments was then used to convert the measured intensities to R6G
concentrations in the venous effluent at the time the sample was collected. The measured
input R6G concentrations were slightly different from the desired 0.25 M, which
created additional variability among the results of experiments using the same
experimental Protocol. To minimize this variability, the concentrations of all venous
effluent samples were scaled by the ratio of 0.25 M to the measured R6G concentration
of the input sample.
Figure 3.6 shows R6G venous effluent concentrations during the three phases of
Protocol 2. Results show that R6G venous effluent concentration decreased from ~ 0.13
M during the loading phase to ~ 0.03 M during the wash phase after switching from
perfusate containing 0.25 M R6G (loading phase) to perfusate with 0 M R6G (wash
phase). Figure 3.6 also shows that perfusing the lungs with perfusate containing FCCP
(~67 M) resulted in a rapid increase in the concentration of R6G in the venous effluent
samples (uncoupling phase), consistent with the uncoupling of lung tissue mitochondria
and the release of R6G that had accumulated in the mitochondria during the loading
phase, driven by Δm. Thus, these data contain information about Δm, which was
quantified using the computational model as described in Data Analysis chapter.
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Figure 3.6: Solid symbols: R6G venous effluent concentrations during the loading phase,
wash phase, and uncoupling phase using FCCP (67 M). Values are mean ± SE (n = 7
for loading and wash phases, and n = 5 for uncoupling phase).

3.5 Effect of inhibitors of the multi-drug efflux pump P-glycoprotein (Pgp) on R6G
lung uptake:
R6G is a known substrate for Pgp (Roerig et al., 2004). Thus, we evaluated the
effect of the Pgp inhibitor verapamil on R6G venous effluent concentrations during the
three phases of Protocol 2. Figure 3.7 shows the concentrations of R6G in the venous
effluent following passage through lungs in which Pgp was inhibited by recirculating
verapamil (0.1 mM) for 3 minutes prior to carrying out Protocol 2. In addition, verapamil
(0.1 mM) was added to the perfusate during all three phases of this Protocol. The results
show no significant increase in R6G uptake during the loading phase (as compared to
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Figure 3.6), but a large increase in the concentration of R6G released from the lungs
following the addition of FCCP to the perfusate (uncoupling phase).
Figure 3.7 also shows that adding just the vehicle (DMSO) for FCCP to the
perfusate during the uncoupling phase had no effect on the concentration of R6G in the
venous effluent compared to that during the wash phase.

Figure 3.7: Solid symbols: R6G venous effluent concentration in lungs following
treatment with verapamil using Protocol 2. Values are mean ± SE. n = 6, 5, 5 for loading
phase, wash phase, and uncoupling phase, respectively. Open symbols: R6G venous
effluent concentration in lungs following treatment with verapamil using Protocol 2 with
DMSO (FCCP vehicle) instead of FCCP added to the perfusate during the uncoupling
phase. Values are mean ± SE (n = 2).

29
3.6 Effects of rat exposure to hyperoxia (>95% O2 for 48 hours) on R6G venous
effluent concentrations using Protocol 2.
48-hr hyperoxia

R6G concentration ( M)

0.25

Lung 1
Lung 2

0.20

0.15

0.10

0.05

0.00
0

5

10

15

Time (min)

Figure 3.8: R6G venous effluent concentration using Protocol 2 in lungs from 2 rats
exposed to hyperoxia for 48 hrs.
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CHAPTER 4: MODEL DEVELOPMENT
4.1 Pharmacokinetic model of R6G pulmonary disposition
For mechanistic and quantitative interpretation of the R6G kinetic data, a
pharmacokinetic model was developed for the pulmonary disposition of R6G. The model
was used to estimate parameters descriptive of the dominant factors that determine the
lung uptake and retention of R6G, including Δm.

Figure 4.1: Pharmacokinetic model of R6G lung uptake and retention on passage
through the rat pulmonary circulation. The model consists of four regions: tubing,
vascular, extravascular (non-mitochondrial), and mitochondrial with volumes Vtub, Vc, Ve
and Vm, respectively. See below for definitions of various symbols and parameters.
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The model (Figure 4.1) includes four regions, namely the tubing region,
consisting of the tubing connecting the reservoir to the pulmonary artery, the lung
vascular region, the extravascular (intracellular, non-mitochondrial) region, and the
mitochondrial region, each with volume Vtub, Vc, Ve, and Vm, respectively. The model
accounts for the hypothesized dominant vascular and/tissue processes that determine the
lung uptake and retention of R6G on passage through the pulmonary circulation. Within
the vascular region, the model accounts for the binding of R6G to BSA, which is
assumed to be rapidly equilibrating with dissociation equilibrium constant Kd1. The
model also accounts for the electrochemical gradients that drive the uptake of R6G from
the vascular region to the extravascular region and from the extravascular to the
mitochondrial region. R6G flux across plasma membrane (J1) or inner mitochondrial
membrane (J2) is represented by a modified one-dimensional Goldman-Hodgkin-Katz
equation (Gan et al., 2011; Huang et al., 2007). Furthermore, the model accounts for the
Pgp pump which pumps R6G from the non-mitochondrial extravascular region back to
the vascular region (Gan et al., 2011). The kinetic model makes no assumptions regarding
the anatomical location of the Pgp protein, although it is assumed that Pgp transports
R6G from the extravascular region back to the vascular region (Gan et al., 2011). At the
concentration of R6G used (0.25 M), we assume that the pump follows first-order
kinetics based on the data in Figure 3.2. Within the extravascular region, the model
allows for slowly equilibrating R6G interactions (Gan et al., 2011). This could represent
intracellular binding or sequestration in organelles, and is assumed to be a high-capacity,
high-affinity pool for R6G (Gan et al., 2011). Within the mitochondria region, the model
accounts for the binding of R6G to various proteins (Scaduto et al., 1999) which is
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assumed to be rapidly equilibrating with dissociation equilibrium constant Kd3. The
inhibitor verapamil is assumed not only to inhibit (competitive inhibition) Pgp- mediated
R6G efflux, but also to compete (non-competitive inhibition) with R6G for binding sites
in the extravascular region (Gan et al., 2011) (see Chapter 6).
The rates of change in the concentrations of R6G in each of the four regions are
described by the following system of differential equations, which were derived using the
laws of mass balance and mass action.
4.2 Derivation of Model Equations
Glossary of terms:
[Be]

Concentration of extravascular R6G binding sites (M)

[Bc] = [BSA]

Vascular BSA concentration (%BSA)

[Pm]

Concentration of mitochondrial R6G binding sites (M)

[Ctub]

Free R6G concentration within the tubing region (M)

[Ce]

Free R6G concentration within the extravascular region (M)

[CeBe]

Concentration of bound R6G within the extravascular region (M)

[Cc]

Free R6G concentration within the vascular region (M)

[CcBc]

Concentration of bound R6G within the vascular region (M)

[Cc ]

Total concentration of R6G within the vascular region (M)

[Cin]

Infused R6G concentration (M)

[Cm]

Free R6G concentration within the mitochondrial region (M)

[CmBm]

Concentration of bound R6G within the mitochondrial region (M)

Q

Flow rate (ml/min)

J1

Dye flux across plasma membrane (nmol/(cm2.min))

J2

Dye flux across inner mitochondrial membrane (nmol/(cm2.min))

k1

Association rate constant of R6G - BSA binding in the vascular region
(%BSA-1.min-1)
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k-1

Dissociation rate constant of R6G-BSA binding within the vascular
region (min-1)

k2

Association rate constant of R6G – Be binding in the extravascular
region (M-1.min-1)

k-2

Dissociation rate constant of R6G – Be binding in the extravascular
region (min-1)

k3

Association rate constant of R6G - Bm binding in mitochondrial region
(M-1.min-1)

k-3

Dissociation rate constant of R6G - Bm binding in mitochondrial region
(min-1)

Kd1 = k-1/k1

Dissociation equilibrium constant for R6G - BSA binding in vascular
region (% BSA)

Kd3 = k-3/𝑘̅3

Dissociation equilibrium constant for R6G - Bm binding in the
mitochondrial region

𝑘̅2 = k2[Be]

Apparent rate constant for R6G – Be binding in the extravascular
region (min-1)

𝑘̅3 = k3[Bm]

Apparent rate constant for R6G - Bm binding in the mitochondrial
region (min-1)

Kpgp

Rate of efflux of R6G via Pgp pump from extravascular to vascular
region (ml/min)

P1

R6G permeability across plasma membrane (cm/min)

P2

R6G permeability across mitochondrial membrane (cm/min)

S1

Surface area of plasma membrane (cm2)

S2

Surface area of mitochondrial membrane (cm2)

V3

Apparent volume of mitochondrial region (ml)

Vtub

Physical volume of tubing region (ml)

Ve

Physical volume of extravascular region (ml)

Vc

Physical volume of vascular region (ml)

Vm

Physical volume of mitochondrial region = 0.02 Ve (ml)
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o

α = ZF/RT

0.0374 mV-1 at 37 C is a constant dependent on the universal gas
constant (R), Faraday constant (F), R6G valence (Z), and absolute
temperature (T).

Δ m

Mitochondrial membrane potential (mV)

Δ p

Plasma membrane potential (mV)

4.2.1 Tubing Region
d [Ctub ] Q
=
([Cin ] − [Ctub ])
dt
Vtub

(4.1)

where [Cin] and [Ctub] are total (free + bound) concentration of R6G in reservoir and
tubing regions, respectively.
4.2.2 Vascular Region
Rates of change in the concentrations of free, [Cc], and BSA-bound, [CcBc], R6G within
the vascular region:
Vc

d [Cc ]
= Vc ( k−1[Cc Bc ] − k1[Cc ][ Bc ]) − S1 J1 + K pgp [Ce ] + Q ([Ctub ] f − [Cc ])
dt

(4.2)
Vc

d [Cc Bc ]
= Vc ( −k−1[Cc Bc ] + k1[Cc ][ Bc ]) + Q ([Ctub ]b − [Cc Bc ])
dt

(4.3)
where Bc = perfusate % BSA, and [Ctub]f and [Ctub]b are the free and BSA bound R6G
concentrations in the tubing region such that,
[Ctub] = [Ctub]f + [Ctub]b
and

(4.4)
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J1 =

 P1 p

(e

 p

(e
− 1)

 p

[Cc ] − [Ce ]

)

(4.5)

Assuming rapidly equilibrating interactions between R6G and perfusate BSA
then,

k−1[Cc Bc ] = k1[Cc ][ Bc ]
[Cc Bc ] =

[C ][ B ]
k1
[Cc ][ Bc ] = c c
k−1
Kd1

(4.6)
(4.7)

where Kd1 is the R6G to BSA binding equilibrium dissociation rate constant. Let

 [B ] 
[Cc ] = [Cc ] + [Cc Bc ] = [Cc ] 1 + c 
 Kd1 

(4.8)

then addition of equations 4.2 and 4.3 after substituting equations 4.7 and 4.8 for free and
bound forms of R6G in the vascular region results in:

Vc

d [Cc ]
= − S1 J1 + K pgp [Ce ] + Q ([Ctub ] − [Cc ])
dt

(4.9)

and


 P1 p   p
J1 = 
e
e p −1 



(

)



[Cc ]
− [Ce ] 

 [ Bc ] 
1
+



Kd1 



(4.10)

4.2.3 Extravascular Region
Rates of change in the concentrations of free, [Ce], and protein-bound, [CeBe],
R6G within this region:
Vc

d [Ce ]
= Ve ( k−2 [Ce Be ] − k2 [Ce ]) − S 2 J 2 + S1 J1 − K pgp [Ce ]
dt

(4.11)
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Ve

d [Ce Be ]
= Ve ( −k−2 [Ce Be ] + k2 [Ce ])
dt

(4.12)

where k2 = k2 [ Be ] and

J2 =

 P2  m

(e

 m

(e
− 1)

 m

[Ce ] − [Cm ]

)

(4.13)

4.2.4 Mitochondrial Region
Rates of change in the concentrations of free, [Cm], and protein-bound, [CmBm],
R6G within this region:
Vm

d [Cm ]
= Vm ( k−3[Cm Bm ] − k3[Cm ][ Bm ]) + S 2 J 2
dt

(4.14)

Vm

d [Cm Bm ]
= Vm ( −k−3 [Cm Bm ] + k3[Cm ][ Bm ])
dt

(4.15)

where [Bm] = protein concentration within mitochondrial region
Assuming rapidly equilibrating interactions between R6G and Bm then:

k−3[Cm Bm ] = k3[Cm ][ Bm ]
[Cm Bm ] =

where K d 3 =

[Cm ]
Kd 3

(4.16)
(4.17)

k−3
is R6G and Bm binding equilibrium dissociation constant.
k3 [ Bm ]

The addition of equations 4.14 and 4.15 after substituting equation 4.17 for
[CmBm] results in


d [Cm ]
1  d [Cm ]
Vm 1 +
= V3
= S2 J 2

dt
 K d 3  dt

(4.18)
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1 
where V3 = Vm 1 +
 is the apparent volume of the mitochondrial extravascular
 Kd 3 
region.
4.2.5 System of governing ODE’s
d [Ctub ] Q
=
([Cin ] − [Ctub ])
dt
Vtub

(4.20)

Vc

d [Cc ]
= − S1 J1 + K pgp [Ce ] + Q ([Ctub ] − [Cc ])
dt

(4.21)

Ve

d [Ce ]
= Ve ( k−2 [Ce Be ] − k2 [Ce ]) − S 2 J 2 + S1 J1 − K pgp [Ce ]
dt

(4.22)

Ve

d [Ce Be ]
= Ve ( −k−2 [Ce Be ] + k2 [Ce ])
dt

(4.23)

V3

d [Cm ]
= S2 J 2
dt

(4.24)

where


 P1 p   p
J1 = 
e
e p −1 



(

J2 =

)

 P2  m

(e

 m

(e
− 1)

 m



[Cc ]
− [Ce ] 

 [ Bc ] 

1 +

Kd1 



[Ce ] − [Cm ]

)

(4.25)

(4.26)

[Ctub](t) and [Cc ](t ) are R6G total (free + bound) concentrations (M) at time t in
the tubing and vascular regions, respectively; [Ce](t) and [Cm](t) are R6G free
concentrations in extravascular and mitochondrial regions at time t, respectively;
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[CeBe](t) is R6G bound concentration in the extravascular region at time t; [Cin] is the
R6G concentration in the reservoir; [Bc] is % BSA in perfusate; [Bm] is the concentration
of R6G binding sites within the mitochondrial region; Q (ml/min) is pump flow; P1S1
(ml/min) and P2S2 (ml/min) are products of R6G permeability (P) across plasma and
mitochondrial membranes, respectively, and the surface area (S) of these membranes;
Kpgp is Pgp-mediated dye efflux rate (ml/min); K d 1 =

k−1
(%BSA) is the dissociation
k1

equilibrium constant for R6G-BSA binding in the vascular region; K d 3 =

k−3
is the
k3[ Bm ]

dissociation equilibrium constant for R6G - Bm binding within the mitochondria region;

1 
V3 = Vm 1 +
 is the apparent volume (ml) of the mitochondrial region; ki and k-i are
K
d
3



R6G and protein/binding sites association and dissociation rate constants, respectively,
with Bc (i =1) and Bm (i = 3), respectively; k2 = k2 [ Be ] (min– 1) and k-2 (min– 1) are rate
constants for R6G binding and unbinding with binding sites Be within Ve, respectively,
o

and [Be] is the concentration of those binding sites; α = ZF/RT = 0.0374 mV-1 at 37 C is
a constant dependent on gas constant, Faraday constant, R6G valence, and absolute
temperature; Δm and Δp are mitochondrial and plasma membrane potential (mV),
respectively.
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Table 4.1: Model Parameters
Symbol
Kd1 = k-1/k1
k2

k-2
Kd 3

Kpgp
P1S1
P2S2
Δ m

Description
Dissociation equilibrium constant for R6G-BSA
binding in the vascular region
Apparent rate constant for R6G-Bc binding within
the cytoplasm region
Dissociation rate constant of R6G-Bc binding
within the cytoplasm region
Dissociation equilibrium constant for R6G-Bm
binding within the mitochondria region
Rate of efflux of R6G via Pgp pump from
cytoplasm to the vascular region
R6G permeability-surface area product across the
plasma membrane
R6G permeability-surface area product across the
mitochondrial membrane
Mitochondrial membrane potential

Units
%BSA
min-1
min-1

ml/min
ml/min
ml/min
mV

The PBPK model R6G extraction ratio (ER) at a given time t, a measure of the
fraction of the input that is extracted on passage through the lungs, is given by the
following equation
̅̅̅]
[𝐶

𝐸𝑅 = 1 − [𝐶 𝑒 ]
𝑖𝑛

(4.27)

4.3 Estimation of Model Parameters
To reduce the number of unknown model parameters, the lung vascular volume (Vc) was
set at 0.85 ml (Audi et al., 2003) and the lung extravascular volume (Ve) was set at 1.0 ml
based on lung tissue water volume estimated from lung wet weight and wet-to-dry weight
ratio (Audi et al., 2003). To break the correlation between Vm and Δm, the ratio Vm/Ve
was set to 0.02, consistent with a lower bound measured for this ratio in rat pulmonary
endothelium (Gan et al., 2011). To break the correlation between P1S1 and Δp, the value
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of Δp was set to that (-43 mV) estimated by Gan et al. in cultured pulmonary arterial
endothelial cells (Gan et al., 2011). Furthermore, we assumed complete dissipation of
Δm in the presence of FCCP at the concentration used (67 M) (Zhao et al., 2013;
Huang et al., 2018), and complete inhibition of Pgp in the presence of verapamil at the
concentration used (100 M) (Roerig et al., 2004). Then, Δm, Kpgp, Kd1, Kd3, 𝑘̅2 , k-2,
P1S1, and P2S2 are the unknown model parameters (Table 4.1). The model-governing
differential equations were solved numerically using the MATLAB (MathWorks)
function “ode45,” which is based on an explicit Runge-Kutta formula. The equations
were solved with the following initial (t = 0) conditions: [Cc ] (0) = [Ce](0) = [Cm](0) = 0
and [Ctub](0) = [Cin] for Protocol 1 and loading phase of Protocol 2, and [Ctub](0) = 0 for
wash and uncoupling phases of Protocol 2.
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CHAPTER 5: DATA ANALYSIS

5.1

Experimental Data Analysis
Data analysis was performed in Excel and Matlab using text files exported from

PTI’s Felix software.
5.1.1

Standard Curve
For each standard R6G concentration, the R6G fluorescent intensity was

determined from the average intensity measurements acquired over a period of 5 seconds.
The average intensity of the sample with no R6G added was considered background, and
this intensity was subtracted from the intensities of samples with different R6G
concentrations. The resulting intensities were then plotted against the known R6G
concentrations added to each standard sample. As shown in Figure 5.1, linear regression
was then used to estimate the slope of the standard curve which was then used to convert
R6G intensity in each lung to R6G concentration.
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Figure 5.1: Representative standard curve for R6G. This is done to have a way of
converting the recorded emission values from experimentation to concentration values.
This procedure was performed for every experimental data set. Values are mean ± SE (n
= 7).

Line (simultaneous fit of protocol 2 no verp + BSA ER data)
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5.2 Fit of PBPK model to data

0.6

ER at 6 min

0.5

Data
Model fit

0.4

*
&*

0.3

#*

0.2
0.1
0.0

0.5%

2.0%

1.0%

3.0%

% BSA
Figure 5.2: R6G lung extraction ratio (ER, solid bars) after 6 min of perfusion (single
pass) as a function of perfusate %BSA. Pump flow = 10 ml/min. Values are mean ± SE
(n = 10, 3, 3 and 4 for perfusate BSA of 0.5, 1.0, 2.0, and 3.0%, respectively. Open bars
are model fit values. *significantly different from 0.5% BSA (P < 0.05, unpaired t-test),
&
significantly different from 1.0% (P < 0.05), and # significantly different from 2.0% (P <
0.05).

44
0.7
0.6

Data
Model predicted

*

ER

0.5

*

0.4
0.3
0.2
0.1
0.0

5 ml/min

10 ml/min

20 ml/min

Figure 5.3: R6G lung extraction ratio (ER, solid bars) after 12 min, 6 min, and 3 min of
perfusion (single pass) with pump flow set at 5, 10, or 20 ml/min, respectively. Values
are mean ± SE (n = 4, 10, and 6 for flow of 5, 10, and 20 ml/min, respectively. Open bars
are model prediction. *significantly different from ER at flow of 10 ml/min (P < 0.05,
unpaired t-test).

0.25 uM R6G (cammarata data)
ER approaches steady state by 6 min (paired t-test show significant difference between 6, and 7-10)
1.0

45

B.

A.
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Data
Model prediction
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Figure 5.4: Panel A: R6G lung extraction ratio (ER) as a function of sampling time on
passage through the pulmonary circulation. R6G reservoir concentration was 0.25 M,
pump flow = 10 ml/min, and perfusate BSA concentration was 0.5%. Panel B: R6G
tubing extraction ratio (ER) as a function of sampling time. R6G reservoir concentration
was 0.25 M, pump flow = 10 ml/min, tubing volume = 4 ml, and perfusate BSA
concentration was 0.5%. Solid line is model prediction. Values are mean ± SE (n = 7, 3
for panels A and B, respectively).

Averaged R6G

R6G venous effluent concentration (M)

46 3)
Concentration (scaled to 0.25 mM) without verapamil (N = 7 for phases 1 and 2, n = 5 for phase
0.25

0.20
Fresh perfusate
Data
Model fit

0.15

0.10

0.05

FCCP

0.00
0
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15

Time (min)

Loading phase

Wash phase

Uncoupling phase

Figure 5.5: Solid symbols: R6G venous effluent concentrations during the loading phase,
wash phase, and uncoupling phase using FCCP (67 M). Values are mean ± SE (n = 7
for loading and wash phases, and n = 5 for uncoupling phase). Solid line is model fit to
data.
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R6G venous effluent concentrationM)
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0.25

Data, FCCP added during the uncoupling phase
Data, FCCP vehicle (DMSO) added during the uncoupling phase
Model fit
Model prediction

0.20

Fresh perfusate

0.15

0.10

0.05

0.00

0

5

10

FCCP or vehicle15

Time (min)
Loading phase

Wash phase

Uncoupling phase

Figure 5.6: Solid symbols: R6G venous effluent concentration in lungs following
treatment with verapamil using Protocol 2. Values are mean ± SE. n = 6, 5, 5 for loading
phase, wash phase, and uncoupling phase, respectively. Open symbols: R6G venous
effluent concentration in lungs following treatment with verapamil using Protocol 2 with
DMSO (FCCP vehicle) instead of FCCP added to the perfusate during the uncoupling
phase. Values are mean ± SE (n = 2). Solid line is model fit to mean of the solid symbols.
Dashed line is model prediction of the open symbols.

For data from Protocol 1, the results (Figure 5.3) are expressed as the extraction
ratio (ER) as a function of flow rate. The flow rate R6G extraction data in Figure 5.3
contains information about PS1. Whereas the R6G extraction data in Figure 5.6 contain
information about kpgp. All the data also contain information about kd2, kd3, and ∆𝑚 .
To characterize the pulmonary pharmacokinetics of R6G, information about its
permeability across the plasma membrane is needed. This information can be obtained by
evaluating the impact of changing perfusate flow rate (and hence pulmonary transit time)
on the lung ER of R6G. A small change in ER with flow would suggest that cell
membrane permeability for R6G is relatively high, whereas a large change would be
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consistent with a significant barrier for the uptake of R6G on passage through the
pulmonary circulation.
5.3 Estimation of model parameters
The first step in the procedure to estimate the unknown parameters was to fit the
mean kinetic data of Protocol 2 in the absence of verapamil (Figure 5.5) and the ER
values at the four different perfusate %BSA (Figure 5.2) simultaneously. The objective
was to obtain an estimate of Kd1 for R6G binding with perfusate BSA, and initial
estimates of the other unknown parameters (Table 4.1). The model fitting was done in
MATLAB® using the lsqcurvefit function to implement the trust-region-reflective
algorithm, an iterative optimization algorithm that readily incorporates bounds on the
values of the parameters.
The estimated values of model parameters that best fit the data along with the
model fits are shown in Table 5.1 and Figures 5.2 and 5.5, respectively. Based on the
estimated values of Kd1 (0.32 %BSA, Table 2), R6G is ~61% bound to BSA in perfusate
that includes 0.5% BSA.

Table 5.1: Values of model parameters estimated by simultaneously fitting the data in
Figures 5.2 and 5.5.
P1S1
P2S2
(ml/min) (ml/min)
45.40

0.71

Kpgp
(ml/min)
6.19

k2
(ml/min)
11.13

k-2
(min-1)

Kd3

Δm
(mV)

Kd1
(%BSA)

0.1223

0.0327

- 118.21

0.32

Next, Kd1 was fixed at the value in Table 5.1, and the other model parameters
were estimated from the kinetic data from individual Protocol 2 experiments without or
with verapamil added to the perfusate (Figures 5.5 and 5.6). In the presence of verapamil,
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the value of Kpgp was set to zero. The estimated values of the model parameters are
shown in Table 5.2 and Figures 5.5 and 5.6. The ability of the model to fit data from
individual experiments is exemplified in Figure 5.7 for Protocol 2 with and without
verapamil added to the perfusate. The estimated values of the model parameters show
that verapamil not only inhibited Pgp, but also had a significant effect on the binding of
R6G in the extravascular region (see Chapter 6).

Table 5.2: Values of model parameters estimated by fitting model to kinetic Protocol 2 data
from individual lungs in absence or presence of verapamil in the perfusate
P1S1
P2S2
Kpgp
k-2
Kd3
Δm
k2
(ml/min) (ml/min) (ml/min)
(min-1)
(mV)
(ml/min)
R6G

48.81
± 0.66

0.82 ±
0.04

8.98 ±
1.55

12.67 ±
0.58

0.111 ±
0.005

0.023 ±
0.002

- 123.8
± 0.8

R6G +
verapamil

46.69 ±
0.32*

1.12 ±
0.16

0

7.00 ±
0.51*

0.172 ±
0.022*

0.016
±0.002*

- 130.6
± 5.2

Values are mean ± SE (n = 6 and 5 without and with verapamil, respectively). *different
from without verapamil (t-test, P < 0.05). Kd1 (%BSA) was fixed at the value in Table
5.1.
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Exp 04/10/2018
0.25

A: Without verapamil
Data
Model fit

R6G venous effluent Concentration (M)
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Figure 5.7: Solid symbols: Representative R6G lung venous effluent concentration vs.
time data using Protocol 2 without (Panel A.) or with (Panel B.) lung treatment with
verapamil. Solid line is model fit.
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5.4 Model Validation
To validate the model, we assessed its ability to predict experimental data that
were not used for model development, including estimation of the values of the unknown
model parameters. To that end, we evaluated the ability of the model to predict the
experimental data in Figure 5.5 at the different pump flows. The kinetic model and the
mean of the estimated best fit values of model parameters without verapamil (Table 5.2)
were evaluated by predicting the effect of pump flow on R6G ER at flows of 5 ml/min
and 20 ml/min (Figure 5.3). The results in Figure 5.3 show that the predicted ER values
are close to the measured values, providing support for the model and the estimated
values of the model parameters (Table 5.2).
5.5 Measures of estimability of the model parameters
The estimability of the model parameters from the Protocol 2 kinetic data in
Figures 5.5 and 5.6 was evaluated using a Monte Carlo approach and sensitivity analysis
(Dutta et al., 1997; Bassingthwaighte et al., 1984). For the Monte Carlo approach, the
model was fit to the Protocol 2 mean data without (Figure 5.5) or with (Figure 5.6)
verapamil and was repeated 100 times with different initial values for the model
parameters. The initial values were determined as the mean of the estimated best fit
values given in Table 5.2 (without or with verapamil) + a uniformly distributed random
value within ± 30% of this mean. The resulting estimated values from the 100 fits are
shown in Table 5.3. The results show smaller standard deviation (SD) for ΔΨm from data
with verapamil (Figure 5.6) compared to no verapamil (Figure 5.5) added to the perfusate
(see Chapter 6).
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Table 5.3: Estimated values of model parameters (Monte Carlo approach): 100 different
fits to mean data in the absence or presence of verapamil with the initial values of model
parameters equal to the mean values of the fits to individual experiments (Table 5.2) ± a
uniformly-distributed random value within ± 30% of this mean error
P1S1
(ml/min)

P2S2
(ml/min)

Kpgp
(ml/min)

R6G

49.37
± 7.27

0.769
± 0.156

13.504 ±
4.768

R6G +
Verapamil

49.19
± 9.11

1.178
± 0.326

0

k-2
(min-1)

Kd3

Δm
(mV)

14.78 ±
2.37

0.118
±
0.013

0.028
±
0.010

- 138.82
± 20.67

7.21 ±
0.63

0.168
±
0.019

0.015
±
0.003

- 128.09
± 13.86

k2
(ml/min)

Values are mean ± SD
The estimability of the model parameters from the Protocol 2 kinetic data in
Figures 5.5 and 5.6 was also evaluated using sensitivity analysis. Parameters values were
set to the mean of the best fit values estimated from the individual experiments (Table
5.2). Figure 5.8 shows the corresponding sensitivity functions that represent the
normalized change in the model-fit for a 1% change in the value of each free parameter.
The results show similarly shaped sensitivity functions for P2S2 and Δm during the
loading phase of Protocol 2, but different shapes during the wash and uncoupling phases.
For the wash phase, the sensitivity function for P2S2 is close to zero, but different from
zero for Δm. This relative similarity between the sensitivity functions of P2S2 and Δm
during the loading and uncoupling phases may reflect a correlation between those two
parameters and is consistent with the relatively large SD for both parameters in Table 5.3.
See Chapter 6 for potential approaches to reduce this correlation.
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Figure 5.8: Model parameter sensitivity functions using Protocol 2 without (top panel)
or with (bottom panel) verapamil. The sensitivity functions show the change in the model
solution given a 1% increase in the value of a given model parameter. Each plot is
normalized to its maximum value.
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5.6 Sensitivity of Protocol 2 experiments to depolarization and hyperpolarization of
Δm:
To assess to ability of Protocol 2, without and with verapamil added to the
perfusate, to detect a change in Δm, model simulations (Figure 5.8) were generated
using the mean values of the estimated parameters in Table 5.2. The value of Δm was
decreased (depolarization) or increased (hyperpolarization) with the values of the other
model parameters set to the mean values in Table 5.2. Results show that the uncoupled
phase is highly sensitive to a change in Δm, and that the sensitivity to Δm
depolarization is larger in the presence of verapamil than in its absence.
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Figure 5.9: Model predictions of the sensitivity of lung R6G venous effluent
concentrations using Protocol 2 to depolarization or repolarization of mitochondrial
membrane potential without (top panel) or with (bottom panel) verapamil. Mean values
of model parameters in Table 5.2 were used to generate these simulations.
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CHAPTER 6: DISCUSSION AND CONCLUSIONS

6.1

Overview and Interpretation of Results:
This thesis describes a fluorometric experimental and computational approach for

evaluating lung tissue Δm in isolated perfused rat lungs using the lipophilic cationic dye
R6G. The approach is based on changes in the lung R6G inlet-outlet perfusate
concentrations before and after uncoupling the lung tissue mitochondria. A
pharmacokinetic model was developed and used for quantitative interpretation of the
resulting kinetic data and for estimating parameters that describe the dominant processes
that determine the disposition of R6G on passage through the rat lungs, including Δm.
The model and estimated parameters were validated by determining their ability to
reasonably predict the effect of pump flow on the extraction ratio of R6G on passage
through the lungs over a wide range of flows. The estimated value of Δm is consistent
with that estimated from cultured pulmonary arterial endothelial cells (Gan et al., 2011).
The lung is a complex organ with multiple vascular and tissue processes
determining the pulmonary disposition of R6G. To overcome this complexity, we used
inhibitors and a variety of perfusion conditions to target the dominant processes that are
hypothesized to determine the pulmonary disposition of R6G. This provided us with
discriminating information about those processes. In addition, we used a computational
model to interpret the data. Computational modeling provides a mechanistic and
quantitative framework that accounts for those processes and allows us to estimate
parameters descriptive of those processes, including Δm (Gan et al., 2011; Roerig et al.,
2004; Gan et al., 2011). The pharmacokinetic model developed in the present study is an
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extension of the model developed by Roerig et al. for the disposition of R6G in rabbit
lungs to evaluate the lung activity of Pgp (Roerig et al., 2004). Unlike the model
developed in the present study, their model did not account for the role of Δm and Δp in
the lung uptake and retention of R6G. For the study by Roerig et al., the objective was to
evaluates the kinetics of the Pgp pump in isolated perfused rabbit lungs.
Generally speaking, a single experimental condition or data set of the type
presented here does not contain sufficient information to estimate the parameters of the
pharmacokinetic model (Gan et al., 2011; Roerig et al., 2004; Gan et al., 2011). Instead, a
diverse set of experimental conditions was needed to provide sufficiently discriminating
information about the dominant processes that determine R6G uptake and retention in the
lung. This approach is needed to break the correlation between some of the model
parameters that describe these processes. Both measures of estimability of model
parameters from the kinetic data using Protocol 2 without or with verapamil (Figure 5.8
and Table 5.3) suggest a relatively high correlation between Δm and P2S2 during the
loading and uncoupling phases, but not during the wash phase. This observation is
consistent with the relatively high standard deviation of the estimated values of Δm and
P2S2 using the Monte Carlo approach (Table 5.3). One approach to reduce this correlation
would be to extend the duration of the wash phase or to include additional experimental
data, such as Protocol 2 under a different flow.
Previous studies using cationic dyes to probe Δm have predominately been
carried out in reduced systems, including isolated mitochondria and cultured cells (Gan et
al., 2011; Audi et al., 2017; Perry et al., 2011; Aiuchi et al., 1982; Johnson et al., 1981;
Scaduto et al., 1999; Mandala et al., 1999; Huang et al., 2007; Chen et al., 1988; Agard et
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al., 2009; Davis et al., 1985; Baracca et al., 2003). Gan at al. developed an approach for
quantifying Δm and plasma membrane potential in cultured pulmonary endothelial cells
based on the disposition of rhodamine dyes in the medium surrounding the cultured cells
(Gan et al., 2011). The experimental and computational approach described in the present
study is an extension of their approach to isolated perfused rat lungs. The estimated value
of Δm in the present study (-124 ± 1 (SE) mV and -131 ± 5 mV without and with
verapamil, respectively) is consistent with that estimated by Gan et al. in cultured
pulmonary endothelial cells (-130 ± 3 (SE) mV and -133 ± 1 mV) using rhodamine 123
and TMRE, respectively) (Gan et al., 2011).
For the present study, R6G was chosen since its uptake is rapid enough to
accumulate within the lung tissue on a single pass through the pulmonary circulation
(Roerig et al., 2004). This is in part due to its relatively high octanol/water partition
coefficient compared to that of other rhodamine dyes such as R123 (Mottram et al.,
2012). Our data are consistent with the large (relative to flow) estimated values of P1S1
for R6G (Table 5.2) and its high permeability in cell membranes in a wide range of cells,
including endothelial cells (Mandala et al., 1999; Loetchutinat et al., 2003). Furthermore,
under the experimental conditions used in the present study (10 ml/min flow, 0.5% BSA,
and 0.25 M input concentration), R6G ER is ~ 0.5 (Figure 5.4A), which is midway
within the 0 to 1 dynamic range for ER, and hence optimal for detection of depolarization
or repolarization of Δm.
Previous studies evaluated the effect of R6G on mitochondrial functions
(Williams et al., 1999; Gear et al., 1974). Using isolated rat liver mitochondria, ARL
Gear showed that R6G at concentration > 1 M can have a significant inhibitory effect
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(Ki ~ 3 M) on mitochondrial membrane potential and ATP-supported calcium
accumulation. Using cultured human skin fibroblasts, Williams et al. showed that cells
cultured (3-8 days) in R6G-containing culture medium experienced poor growth for R6G
concentrations as low as 1.2 M. In addition, this prolonged cell treatment with R6G
significantly decreased the number of intact mitochondrial and electron transport chain
enzyme activities. For the present study, the concentration of R6G in the lung perfusate
was 0.25 M, well below the 1 M at which toxic effects on mitochondrial functions
were observed, and the lungs were perfused with this concentration for 10 minutes. In
addition, the binding or R6G to BSA in perfusate decreased the concentration of perfusate
R6G available for cellular uptake to closer to 0.125 M. Thus, for the present study the
experimental conditions, including the chosen R6G concentration, minimized the
potential effects of R6G on mitochondrial functions.
Comparison of the data in Figure 5.7 shows that lung treatment with verapamil
had no effect on the uptake and retention of R6G during the loading phase, although it
had a significant effect during the uncoupling phase of Protocol 2. Model simulations
(not shown) revealed that this increase cannot be explained by just the inhibition of the
Pgp pump, and in fact the R6G efflux concentration was predicted to decrease during the
uncoupling phase. The estimated values of the model parameters (Table 5.2) suggest that
verapamil not only inhibited the Pgp pump, but also competed with R6G for the slowly
equilibrating binding sites in the extravascular region. This effect countered the increase
in lung uptake of R6G due to the inhibition of the Pgp pump, and allowed the R6G
released from the mitochondrial region into the extravascular region during the
uncoupling phase to diffuse quickly into the vascular region driven by the increase in the
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concentration gradient of free R6G across the plasma membrane (Roerig et al., 2004; Cho
et al., 2000).
Unlike the results of the present study, Roerig et al. showed a significant increase
in R6G lung uptake in the presence of verapamil compared to in its absence in isolated
perfused rabbit lungs (Roerig et al., 2004). This could be due to the relatively large rate
of Pgp-mediated R6G efflux compared to that for cytosolic R6G binding in rabbit lungs
(1.44 min-1 vs. 0.23 min-1) (Roerig et al., 2004). For rat lungs, the rate of Pgp-mediated
R6G efflux was comparable to that for cytosolic R6G binding (13.5 min-1 vs. 14.8 min-1)
(Table 5.2). In addition, for the rabbit lungs, the rate of Pgp-mediated R6G efflux is an
order of magnitude larger than the rate of R6G efflux by diffusion across the cell
membrane, whereas in the rat lungs P1S1 was much larger than the rate of Pgp-mediated
efflux (Table 5.2).
One question that could be addressed using the proposed computational model is
the sensitivity of Protocol 2 to a change in Δm in the presence or absence of verapamil.
Model simulations (Figure 5.8) show that Protocol 2 in the presence of verapamil has a
higher sensitivity to depolarization of Δm than in the absence of verapamil. This is in
part due to a decrease in the competition between cytoplasm binding and mitochondria
for free R6G in the cytoplasm. This and the reduction in the number of unknown
parameters for Protocol 2 in the presence of verapamil suggest that Protocol 2 in the
presence of verapamil is preferable for evaluating Δm in isolated perfused lungs for
conditions expected to cause dissipation of Δm.
Scaduto et al. attempted to probe Δm in isolated perfused rat hearts by
monitoring the surface emission fluorescence of the cationic rhodamine dye tetramethyl
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rhodamine methyl ester perchlorate (TMRM) following its addition to perfusate that was
recirculated through the heart (Scaduto et al., 1999). However, the results with a
mitochondrial uncoupler and substrate-free perfusate were difficult to interpret in part
because of alteration in the fluorescent properties of TMRM in heart tissue due to
accumulation of TMRM in both mitochondria and cytosol (Scaduto et al., 1999). The
approach described in the present study overcame this limitation by 1) determining the
lung uptake of R6G from the lung inlet and outlet R6G perfusate concentrations on
passage through the pulmonary circulation instead of from lung surface measurements,
and 2) by using computational modeling for quantitative interpretation of the resulting
kinetic data and for estimating parameters descriptive of the dominant vascular and tissue
processes that determine lung uptake and accumulation of R6G, including Δm.
Hough et al. (JCI 4(3): e124329, 2019) used the fluorescent cationic dye
tetramethylrhodamine ethyl ester (TMRE) to assess the effect of acute chemical lung
injury on mitochondrial membrane potential of microvascular endothelial cells in isolated
perfused mouse lungs. For that study, the lungs were loaded with TMRE by recirculated
perfusate containing TMRE (2 M) for 20 min, followed by a 10-min buffer washout.
Acute chemical injury was then induced by microinfused concentrated hydrochloric acid
(HCl) in the alveolar lumen using alveolar micro puncture technique. Confocal
microscopy was used to measure TMRE fluorescent intensity in micro vessels in the
injured local region before and after injury with HCl. Change in measured TMRE
fluorescence was then used as measure of a change in Δm. Although this approach
allows for assessing a change in endothelial TMRE fluorescence, it has many limitations.
First, it provides a measure of local change in TMRE fluorescence, which may not be
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reflective of the overall change in the lung. This especially true for many lung injury or
disease, which is heterogeneous affecting some lung regions/lobes more than others.
Second, a common pitfall in interpreting such data is that the logarithmic form of the
Nernst equation specifies that changes in fluorescence intensity are not linearly
proportional to changes in Δm. For instance, a 50% decrease in ratio to mitochondrial to
cytosolic dye fluorescence translates to just 17% change in Δm. Third, this approach
does not account for the fact that dyes such as TMRE are also Pgp substrates. For cell
types that have few or no multidrug transporters, this may be of minimal importance, but
multidrug transporters perform a key function in the pulmonary endothelium (Roerig et
al., 2004). A change in Pgp activity will have an effect on TMRE mitochondrial
fluorescence intensity. This effect could be misinterpreted to represent a change in Δm.
Fourth, this approach requires loading the cells with TMRE by recirculating it through
the lungs at a relatively high concentration (2 M) for 20 min. TMRE accumulates in the
mitochondrial matrix driven by Δm. The approach is confounded by the propensity of
dyes such TMRE to undergo self-aggregation, quenching, and photobleaching and/or to
exert phototoxic effects (Scaduto et al., 1999). This affects the utility of a change in
measured mitochondrial TMRE fluorescence as an index of a change in Δm. The
experimental and computational approach described in this thesis overcomes many of
these limitations.
For the present study, the value of Δp was fixed to that estimated by Gan et al.
from cultured pulmonary endothelial cells (Gan et al., 2011). Previous studies have
demonstrated a key role for Δp in regulating channel-mediated calcium entry in
response to mechanical stimuli, oxidative stress, ischemia, and hypoxia (Campbell et al.,
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1991; Koliwad et al., 1996; Paffett et al., 2007; Stevens et al., 1994; Chatterjee et al.,
2006). As such, Δp could be altered by injury or disease. One could obtain information
about Δp by evaluating the impact of its depolarization on R6G lung uptake and
retention. This could be done by perfusing the lungs with perfusate containing high
potassium as was done by Gan et al. in cultured endothelial cells (Gan et al., 2011) or by
Al-Mehdi et al. in isolated perfused rat lungs (Al-Mehdi et al., 1997). Another approach
would be to use fluorescent dyes sensitive to Δp such as the anionic probe bis-oxonol
(Al-Mehdi et al., 1997; Zhang et al. 2005).
The lung vascular volume (Ve) was also fixed to that estimated from normal rat
lungs (Audi et al., 2003). Lung injury, including oxidative stress, has been shown to
change lung vascular and extravascular volumes (Audi et al. 2005; Crapo et al., 1980).
An independent estimate of Ve could be obtained using lipophilic amines and indicator
dilution methods in isolated perfused lungs as previously described (Audi et al., 2005;
Ramakrishna et al., 2010).
The lung consists of 40 different resident cell types (Kotton et al., 2014; Dinh et
al., 2017). The results using R6G provide no direct information regarding the
contributions of the different cell types to the measured R6G lung uptake and estimated
Δm, although endothelial cells would be expected to dominate because of their large
surface area and high fraction (~50%) of total lung cells, and their direct contact with
R6G in perfusate (Crapo et al., 1980). Although the question regarding the contributions
of specific cell types will be important for future studies, alteration in the lung R6G
uptake and estimated Δm as an index of pulmonary mitochondrial dysfunction has
functional implications regardless of the lung cell types involved.
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We and others have reported various measures of mitochondrial dysfunction in
intact lungs, pulmonary endothelial cells in culture, and isolated mitochondrial in
response to oxidative stress (Gan et al., 2011; Audi et al., 2017; Sepehr et al., 2013; Gan
et al., 2011; Ma et al., 2018; Audi et al., 2008; Merker et al., 2007; Pruijn et al., 1992).
The proposed approach will allow us to quantify the effect of oxidative stress on Δm in
intact functioning lungs.
Preliminary results from lungs of rats exposed to hyperoxia show a decrease in
R6G venous effluent concentration following the addition of FCCP. This suggest that the
mitochondria in hyperoxic lungs is less coupled as compared to those in control lungs.
This observation is consistent with the results from studies in mitochondria isolated from
lungs of rats exposed to hyperoxia for 48 hours, which show a significant decrease in the
activities of complex I and complex II, and prolonged ADP-stimulated Δm
depolarization (Audi et al., 2017). Experimental data in the presence of verapamil are
needed to account for the effect of potential hyperoxia-induced change in Pgp activity on
R6G venous effluent concentration.
6.2

Conclusions:
In conclusion, we present a novel experimental and computational approach for

probing and estimating Δm in intact lungs. The approach has the potential to provide
quantitative assessment of the effect of various injurious conditions on lung
mitochondrial function, and to evaluate the impact of therapies that target the
mitochondria. The proposed approach can also be easily adapted for other organs or
cationic dyes.
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APPENDIX
A. Preparation of Stock solutions:
A.1 FCCP Preparation and Fractionation:
Molecular Weight of FCCP: 254.17 g
DMSO Solubility: Up to 10 mM
We have a 10 mg bottle of FCCP
For a 100 M stock of FCCP, what volume of DMSO is needed?
-

1 mole of FCCP → 254.17 g

-

? → 10 ∗ 10−3 g
𝑥=

10∗10−3 𝑔∗𝑚𝑜𝑙
254.17 𝑔

100 𝑚𝑀 =
𝑥=

0.03934 𝑚𝑚𝑜𝑙

0.03934 𝑚𝑚𝑜𝑙
100

= 0.03934 𝑚𝑚𝑜𝑙

𝑚𝑚𝑜𝑙
𝐿

𝑥

= 0.3934 𝑚𝐿

For a perfusate concentration of 50 M FCCP:
-

Reservoir volume is 25 mL

-

Add 12.5 L (0.05% DMSO) of stock per 25 mL in reservoir for a final
concentration of 50 M
Stock Fractionation:

-

10 mg → 0.3934 mL DMSO

-

Fractionate → 25 L volumes

-

This gives us a total of 15 vials we can use

-

Freeze

A.2 Verapamil HCL Preparation:

(A.1.1)
(A.1.2)
(A.1.3)
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Important Information:
-

Molecular Weight = 491.069 g/mol

-

Soluble in H2O (83 mg/mL)

-

Previous study used 0.1 mM

1.) 5 mg = 10.18 umol in 10 mL DH2O = 1.018 mM
2.) Or add 5 mg to 100 mL perfusate for final concentration of 0.1 mM
A.3 Preparation of Perfusate:
0.5% BSA and 2.5% Ficoll
i. Take BSA jar first out of fridge to cool down before opening it.
ii. Prepare a bottle of DH2O.
iii. Take a beaker with the proper volume, label it, and add a stirring stick into it.
Then Add a proper volume of DH2O, the amount is the total volume minus 50
mL for each 300 mL.
iv. Place the beaker on the heater, set the stir as ‘2’ (no heat).
v. Calculate/add the following chemicals required, for 100 mL (0.5% BSA 2.5%
Ficoll),
Add stock in order, weigh the assigned quantity of stuffs, and add them into the
beaker
Stock (in
Fridge)

KCL,
0.5 mL

CaCl2 ,
0.5 mL

MgSO4 , 0.5
mL

KH2PO4 ,
0.5 mL

Chemicals
(on the
shelves)
Note: use
separate
spatula for
each
chemical

NaCl,
0.69 g

Dextrose,
0.1 g

Sodium
Bicarbonate,
0.21 g

BSA, 0.5 g

Papaverine,
0.06 g

Ficoll,
2.5 g

Note: Please keep the table clean always. Clean the electronic balance after all
stuffs have been weighed.
Note: Papaverine is used as a vasodilator to prevent smooth muscle cells within the
lung from constricting and therefore increasing pressure which in turn leads to
edema and tissue death.
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Note: Addition of Papaverine slightly lowers the pH value.
vi. Take a glass stir bar and push BSA into solution.
vii. Put a piece of parafilm on to cover the beaker to prevent contamination and to
keep it stirring until all BSA is in solution (15-20 min).
viii. Use a graduated cylinder to bring the solution to the desired volume and then
place the solution into a clean saline bottle with labels including date and
contents.
Note: Place the label on the shoulder of the bottle to prevent from getting wet.
ix. Empty the beaker content into a plastic bottle. Use a cone (with a cotton
gauze to filter out any particulate in the Perfusate).
x. Place the bottle into the warm water bath (37 ᵒC) for ten minutes.
xi. Prepare the gas mixture in the balloon.
a.) Take a gas balloon.
b.) Turn on all the tanks, using fine adjustment valves to set the parameter as
(settings of stainless steel balls) N2=7, O2=38, CO2=120.
c.) Close the three-way stopcock to the balloon and begin filling the balloon with
the gas mixture for about 5 minutes. Then insert a cork into the tubing and turn
off all the tanks.
d.) Withdraw a syringe of mixture gas in the balloon, and check the gas ingredients
with the blood gas analyzer. Reference value: O2: 16%, CO2: 5%.
e.) Cut the tubing long enough to reach from the pump to the bottom of bottle, turn
the three-way valve open to the balloon.
f.) Allow the gas mixture to bubble for about 20 minutes, check the pH at intervals
– use a syringe with long needle, withdraw about 1 mL and check the pH with
the blood gas analyzer. Reference Value: O2:120-140 mmHg, Co2: 35-40
mmHg and pH: 7.4.
Note: If the pH is high, then keep bubbling, if the pH is too low, then prepare for
another gas balloon without CO2 and bubble the Perfusate with this gas mixture.
g.) When BSA is ready, begin to prepare for other stuffs and the perfusion system.
𝐶𝑂2 + 𝐻2 𝑂 ↔ 𝐻2 𝐶𝑂3 ↔ 𝐻𝐶𝑂3− + 𝐻 +
Law of pH
>7.4: too little hydrogen and too much CO2
- bubble w/ CO2 to drive reaction.
<7.4: too much hydrogen and too little CO2
- bubble w/ air to drive reaction.
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A.4 R6G Stock Procedure:
Note: Prepare and use solutions on the same day. However, if there is a need to
make up stock solutions in advance, it is recommended that you store the
solution as aliquots in tightly sealed vials at -20°C. These solutions will be
viable for up to one month. Allow the solution to equilibrate to room
temperature for at least 1 hour before using.
•
•

Molecular weight of R6G: 479.02 g/mole
Mix 1 mg R6G powder with 1 mL H2O to make Stock 1
- This yields a concentration of 2.09 mM
• Then dilute by taking 40 uL of the stock and add it to 1.96 mL H2O to make
Stock 2
- This gives a stock concentration of 41.8 uM
- Now add 0.7177 mL of Stock 2 to 120 mL perfusate to get an R6G
concentration of 0.25 uM in the perfusate
B. PTI Software Setup:
1) Open the Felix software.
2) Select the Rhodamine 6G macro.
3) Select ‘Set up’.
4) Select ‘Time based’
5) Select the acquisition settings tab in the set-up window.
6) Switch the excitation wavelength to 525 nm.
7) Change the acquisition time to 2000 seconds.
C. Experimental setup/procedure:
R6G Single Pass Experiment
Materials Needed:
•
•
•
•
•
•

Dark marker for labeling
One beaker labeled for perfusate only
One beaker labeled for R6G and perfusate
One beaker labeled for R6G, perfusate, and verapamil
Plastic beaker for waste
One beaker and one squirt bottle for deionized water
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•
•
•
•
•
o
•
•
•
•
•

Large and smalls syringes with tubing for rinsing cuvette
R6G stock
Verapamil and/or FCCP
2.5% Ficoll-Krebs/0.5% BSA perfusate
(74 - 1.7mL) Eppendorf tubes for samples to be centrifuged in
42 for single pass, 8 for wash, and 24 for uncoupler. Have extras on hand.
Micropipettes (two P1000’s for 717.7 L and 1000 L and one P200 for FCCP)
Labels for eppendorf tubes need to be the same as timer (no time for
conversions during experiment)
Stirring rod
Extra eppendorf holder for eppendorfs used during collection
Cuvette vacuum cleaner device

Methods:
Excitation Wavelength: 525 nm
Emission Wavelength: 565 nm
Notes: Then take the cuvette measurements at the end of the experiment. Make sure
all equipment is turned on and warmed up 30 minutes prior to experiment (i.e.
water bath). Practice time callouts before IPRL experiment.
If using Verapamil:
•
•
•
•
•
•
•

Wash with regular perfusate for 5 minutes to rinse out any R6G and/or blood
Add Verapamil to perfusate without R6G
Flow: 10 mL/min
Recirculate for 3 minutes
Then turn the pump off
Drain the perfusate
Begin procedure below but add verapamil perfusate to the system

If not using Verapamil:
•
•
•
•
•
•

Turn pump off
Add 717.7 L R6G stock to 120 mL perfusate (0.02 mg/mL) = 0.25 M
Stir with glass stirring rod
Add perfusate w/o R6G to reservoir
Take “Background” sample now from the normal perfusate (use 2 - 1.7 mL
eppendorf tubes)
Drain the perfusate w/o R6G from the reservoir
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•

Add 50 mL perfusate w/R6G to the reservoir then continuously add more to
keep reservoir from becoming empty and allowing air to enter the system
• Take “0” sample now (use 2 - 1.7 mL eppendorf tubes)
• Turn pump on
• Draw samples out at 40 seconds, 60 seconds, 1:20, 1:40, 2, 2:20, 2:40, 3, 3:20,
3:40, 4, 4:20, 4:40, 5, 6, 7, 8, 9 and 10 minutes (use 2 - 1.7 mL eppendorf tubes
per sample time)
• With flow rate of 10 mL/min fill tubes for 6 seconds each.
o Do this by taking samples 6 seconds before and after the times stated above.
• Stop the flow and wash the reservoir (perform this as quickly as possible).
• Rinse the system/lung for 3 minutes (single pass) with perfusate without R6G.
o Make sure to get a new baseline for each new condition (i.e. wash) before
turning the pump back on.
o Measure for 3 minutes taking samples at 1, 2, and 3 minutes (use 2 - 1.7 mL
eppendorf tubes per sample time)
• Stop the flow and wash the reservoir (perform this as quickly as possible).
• Next add the uncoupler (FCCP) to perfusate without R6G and measure the
effects.
o Make sure to get a new baseline for each new condition (i.e. FCCP) before
turning the pump back on.
o Measure for 7 minutes taking samples at 13:20, 13:40, 14, 14:20, 14:40, 15, 16,
17, 18, 19, and 20 minutes (use 2 - 1.7 mL eppendorf tubes per sample time)
• All samples are spun for 1 minute in the centrifuge @ 10.5 x 1,000 RPM @ 4ᵒC
• Add each time sample (from 2 eppendorf tubes) to a single cuvette and measure
for fluorescence.
• Make sure to use only one cuvette but rinse it with deionized water before
taking any measurements.
D. Standard Curve:
Materials Needed:
•
•
•
•
•
•
•

Cuvette
Micropipettes (two P1000’s for 1 mL and 0.25 mL, one p5000 for 2.25 mL, and
one P100 for 53.82 L)
5 large tubes for doing the mixing/dilution
2.5% Ficoll-Krebs/0.5% BSA perfusate
(12 - 1.7mL) Eppendorf tubes for samples to be centrifuged in
Labels for eppendorf tubes
Extra eppendorf holder for collection eppendorfs
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Methods:
•
•

Get “zero” sample of perfusate without R6G
Add 53.82 L of R6G Stock 2 to 4.5 mL of perfusate in a large tube to get a
concentration of 0.5 M
• Dilute by taking 2.25 mL of the perfusate w/ R6G and mixing it with 2.25 mL
of the perfusate w/o R6G to get a concentration of 0.25 M
• Dilute by taking 2.25 mL of the previous perfusate w/ R6G and mixing it with
2.25 mL of the perfusate w/o R6G to get a concentration of 0.125 M
• Dilute by taking 2.25 mL of the previous perfusate w/ R6G and mixing it with
2.25 mL of the perfusate w/o R6G to get a concentration of 0.0625 M
• Dilute by taking 2.25 mL of the previous perfusate w/ R6G and mixing it with
2.25 mL of the perfusate w/o R6G to get a concentration of 0.03125 M
• Now place 1 mL in each eppendorf tube (2) per concentration
• Then place them symmetrically in the centrifuge for 1 minute @ 10. 5 x 1,000
RPM @ 4ᵒC
• Use single cuvette and rinse before each measurement with deionized water
• Make sure to start with lowest concentrations first and end with highest
concentrations to avoid harmful binding effects
• Place supernatant (from 2 eppendorf tubes per concentration) into cuvette and
take sample of fluorescence
• Use data to create standard curve in sigma plot or excel
E. Matlab Code:
E.1 r6g_single_pass_sim.m

function r6g_single_pass_sim
%%
clear all
close all
clc
global deltap F
%% Values of model parameters
vmaxkm = 13.989154; %18.7;% Kpgp Rate of efflux of R6G from pgp pump
(ml/min)
k2_bar = 11.147875;% Apparent rate constant for R6G-Bc binding within the
cytoplasm region(min-1)
kminus2 = 0.093307;%Dissociation rate constant of R6G-Bc binding within the
cytoplasm region (uM-1*min-1)
kd3 = 0.019121;%Dissociation equilibrium constant for dye-protein binding in
the mitochondria region (umol-1*min-1)
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ps2 = 0.837797;% dye permeability-surface area product across mitochondria
membrane (ml/min)
deltam = 122.558453; % Mitochondrial membrane potential (mV)
deltam_un =0.1; %68; % mitochondrial membrane potential after uncoupler is
added (mV)
%fixed
deltap = 43; %40 Plasma membrane potential (mV)
F = 10; %Flow (ml/min)
%%--------------% plot(tt,blood_tissue_region)
Ce_bar = 0; %Total initial vascular R6G concentration (uM)
Cc = 0; %Total initial tissue R6G concentration (uM)
Cm = 0; %Total initial mitochondrial R6G concentration (uM)
CcBc = 0; % Total intial bound r6g cytoplasm concentration (uM)
Ctub1 = 0; % Total intial tubing r6g concentration (uM)
%Ctub2 = 0; % Total intial tubing r6g concentration (uM)
%Ctub3 = 0; % Total intial tubing r6g concentration (uM)
%Ctub4 = 0; % Total intial tubing r6g concentration (uM)
% show the values of parameters during optimization process
% parameter_values = p;
parameter_values(1) = ps2;
parameter_values(2) = k2_bar;
parameter_values(3) = kminus2;
parameter_values(4) = kd3;
parameter_values(5) = deltam;
parameter_values(6) = deltam_un;
parameter_values(7) = vmaxkm;

%% calling to function solving ODE's
ttdata = [0:0.1:20]';
options=odeset('InitialStep',1e-10,'RelTol',1e-10,'Refine',1);%,'NormControl','on');
% temp = parameter_values;
x0 = [Ctub1 Ce_bar Cc Cm CcBc]; % mass/volume aka concentration input
calculated based off real experimental values (uM)
% calling to ode
[tfinal,xfinal] = ode45(@r6g_odes, ttdata, x0, options, parameter_values);
%% open file, read experimental data to be fit
figure
plot(tfinal, xfinal(:,2), ttdata, xfinal(:,2))
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infile = 'sim.txt';
fid = fopen(infile, 'w');
%% read data from fil
for i=1:length(ttdata)
fprintf(fid,'%f %f\n', tfinal(i), xfinal(i,2));
end
fclose(fid);
%get data
E.2 r6g_odes.m

function [ x_dot ] = r6g_odes(ttdata,x, parameters)
global deltap F
% define parameters
Ve = 0.85; %Physical lung vascular volume = 1 ml
Vc = 1; %Physical lung tissue volume = 1 ml
Vm = 0.02*Vc; %Physical lung mitochondrial volume = 0.01*Vc (ml)
Vtub = 4; % measured Physical tubing volume (ml)
alpha = 0.0374158; %ZF/RT where Z is the valency of the ions (Na+, Ca2+, and
Cl-), F is Faraday’s constant ...
...(9.684 x 104 C/ mol), R is the gas constant (8.135 J/K*mol), and T is the
absolute temperature in K (273 + temp in Celcius). (mV-1)
Be = 0.5; %[BSA] Total vascular protein (BSA) concentration (uM)
kd1 = 0.32;%15; %k-1/k1 %Dissociation equilibrium constant for dye-protein
binding in the vascular region (umol-1*min-1)
ps1 = 50.558129;
%%%%%%%%%%%%%%%%%
ps2
= parameters(1);
k2_bar
= parameters(2);
kminus2 = parameters(3);
kd3
= parameters(4);
deltam
= parameters(5);
deltam_un = parameters(6);
vmaxkm
= parameters(7);
% calculate the apparent volumes
V3 = Vm*(1+(1/kd3)); %Apparent mitochondrial volume (ml)
%create vector of zeros
x_dot = zeros(5,1);
% get last time point from data gathered
time = 20;
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% varying Cin based off phase and deltam
if ttdata >= 0 && ttdata <= (time-9.6) % phase 1... loading phase
Cin = 0.25;
elseif ttdata > (time-9.6) && ttdata <= (time-6.6) % phase 2... wash phase
Cin = 0;
elseif ttdata > (time-6.6) % phase 3... uncoupler phase
Cin = 0;
deltam = deltam_un; %Mitochondrial membrane potential (mV)
end
% Free concentration of r6g within the vascular region
Ce = (x(2)/(1+(Be)/(kd1))); %units = nmol/mL or umol/L
% calculate flux values
J1 = ((alpha*ps1*deltap)/(exp(alpha*deltap)-1))*(exp(alpha*deltap)*Ce-x(3));
%Dye flux across plasma membrane (nmol/min)
J2 = ((alpha*ps2*deltam)/(exp(alpha*deltam)-1))*(exp(alpha*deltam)*x(3)-x(4));
%Dye flux across inner mitochondrial membrane (nmol/min)
% ODE's - do differential computations here
x_dot(1,1) = (1.0/(Vtub))*F*(Cin-x(1)); % tubing region
x_dot(2,1) = (1/Ve)*(-J1+vmaxkm*x(3)+F*(x(1)-x(2))); % extracellular/vascular
region units = nmol/mL*min
x_dot(3,1) = kminus2*x(5)-k2_bar*x(3)+(1/Vc)*(J1-J2-vmaxkm*x(3)); %
cytoplasm region free
x_dot(4,1) = (1/V3)*(J2); % mitochondrial region units = nmol/mL*min
x_dot(5,1) = k2_bar*x(3)-kminus2*x(5); % cytoplasm region bound
end
E.3 r6g_fit_v3_single.m

function r6g_fit_v3
% % initial cleanup
clear all
close all
clc
global deltap F tt deltam_un
%% open file, read experimental data to be fit
infile = 'conc_data_041018.txt';
fid = fopen(infile, 'r');
%% read data from file
data150 = textscan(fid,'%f %f');
fclose(fid);
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%get data
tt = (data150{1});
blood_tissue_region=(data150{2});
% plot(tt,blood_tissue_region)
figure
plot(tt, blood_tissue_region)
%% initialize and do lsqcurvefit
% define the data which will be used to estimate parameters
indata = [blood_tissue_region];
% define the corresponding sampling time points
ttdata = [tt];
%%%%%
figure
subplot(2,1,1)
plot(ttdata,indata,'ko')
% legend('Data','Fitted Curve')
title('Data and Fitted Curve from Residuals')
xlabel('Time (minutes)')
ylabel('Concentration (uM)')
hold on
for i =1:1
%% define initial values for the unknown parameters
vmaxkm = 8.840851;% Kpgp Rate of efflux of R6G from pgp pump (ml/min)
k2_bar = 12.475779;% Apparent rate constant for R6G-Bc binding within the
cytoplasm region(min-1)
kminus2 = 0.110531;%Dissociation rate constant of R6G-Bc binding within the
cytoplasm region (uM-1*min-1)
kd3 = 0.02313;%Dissociation equilibrium constant for dye-protein binding in the
mitochondria region (umol-1*min-1)
ps2 = 0.83082;% dye permeability-surface area product across mitochondria
membrane (ml/min)
deltam = 123.11; % Mitochondrial membrane potential (mV)
deltam_un = 0.1; % mitochondrial membrane potential after uncoupler is added
(mV)
ps1 = 49.4309;
%fixed
deltap = 43; %40 Plasma membrane potential (mV)
F = 10; %Flow (ml/min)
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% define the optimization options
options = optimset('Algorithm', 'trust-region-reflective', 'MaxFunEvals', 3000,
'TolFun', 1e-15,'TolX',1e-10);
%% no verapamil fitting
% define the parameters which will be estimated
p0 = [ps2, k2_bar, kminus2, kd3, deltam, vmaxkm, ps1];
% define the lower bound of parameters
%lb = 0.0001*ones(length(p0),1);
lb = [0.0001, 0.0001, 0.0001, 0.0001, 110, 0, 0.001];
% define the upper bound of parameters
% ub = [200 200 200 200 200 200 1 200];%
ub = 300*ones(length(p0),1); %[20 20 20 20 20 20];
% fitting model to input data and find out the optimized values for parameters
[p, ssd, residual, ef, outt,lambda, jacobian] =
lsqcurvefit(@r6g_single_pass_param_est_v3, p0, ttdata, indata, lb, ub, options);
%%%%%%
PPAR(i,1) = p(1);
PPAR(i,2) = p(2);
PPAR(i,3) = p(3);
PPAR(i,4) = p(4);
PPAR(i,5) = p(5);
PPAR(i,6) = p(6);
PPAR(i,7) = p(7);
fit_conc = indata+residual;
plot(ttdata, fit_conc,'b-')

end
p(1) = mean(PPAR(:,1))
p(2) = mean(PPAR(:,2))
p(3) = mean(PPAR(:,3))
p(4) = mean(PPAR(:,4))
p(5) = mean(PPAR(:,5))
p(6) = mean(PPAR(:,6))
p(7) = mean(PPAR(:,7))
%%%%%%
PPAR(:,1)
PPAR(:,2)
PPAR(:,3)
PPAR(:,4)
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PPAR(:,5)
PPAR(:,6)
PPAR(:,7)
% residual = model fit - data
%
%correlation matrix
NP = length(p0);
h = inv(jacobian'*jacobian);
for i = 1:NP;
for j = 1:NP;
cc(i,j) = h(i,j)/((h(i,i)*h(j,j))^0.5);
end
end
full(cc)
%confidence intervals (95% confidence, alpha = 0.05)
s_2 = ssd/(length(indata) - NP);
for i = 1:NP;
seb(i) = ((s_2)^0.5)*(h(i,i)^0.5);
end
alpha = 0.05;
tt_dis = - tinv(alpha/2, length(indata) - length(p0)); % tinv is the Student's t
inverse cumulative
%distribution function
seb = seb.*tt_dis;
seb
%%%%%%%%

%
%
%
%
%
%

%
%
%
%
%

figure
plot(ttdata, jacobian(:,1))
figure
plot(ttdata, jacobian(:,2))
figure
plot(ttdata, jacobian(:,3))
figure
plot(ttdata, jacobian(:,4))
figure
plot(ttdata, jacobian(:,5))
figure
plot(ttdata, jacobian(:,6))
figure
plot(ttdata, jacobian(:,7))
figure
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% display the optimized values of parameters and related results
% fprintf('result:\n PS1 = %f +/- %f ml/min\n', p(1), ci(1,1));
fprintf(' PS2 = %f ml/min\n', p(1));
% fprintf(' kd1 = %f +/- %f Percent BSA\n', p(3), ci(1,3));
fprintf(' k2_bar = %f min-1\n', p(2));
fprintf(' kminus2 = %f min-1\n', p(3));
fprintf(' kd3 = %f uM\n', p(4));
fprintf(' deltam = %f mV\n', p(5));
% fprintf(' deltam_un = %f mV\n', p(6));
fprintf(' VmaxKm = %f ml/min\n', p(6));
fprintf(' ps1 = %f ml/min\n', p(7));
% fprintf(' deltap = %f +/- %f mV\n', p(8), ci(1,8));
fprintf(' deltap = %f mV\n', deltap);
fprintf(' SSD = %f\n', ssd);
end
E.4 r6g_single_pass_param_est_v3.m

function Out = r6g_single_pass_param_est_v3(p, ttdata)
global deltap F tt deltam_un
%% Initial values for ODEs
Ce_bar = 0; %Total initial vascular R6G concentration (uM)
Cc = 0; %Total initial tissue R6G concentration (uM)
Cm = 0; %Total initial mitochondrial R6G concentration (uM)
CcBc = 0; % Total intial bound r6g cytoplasm concentration (uM)
Ctub1 = 0; % Total intial tubing r6g concentration (uM)
%Ctub2 = 0; % Total intial tubing r6g concentration (uM)
%Ctub3 = 0; % Total intial tubing r6g concentration (uM)
%Ctub4 = 0; % Total intial tubing r6g concentration (uM)
% show the values of parameters during optimization process
% parameter_values = p;
parameter_values(1) = p(1);
parameter_values(2) = p(2);
parameter_values(3) = p(3);
parameter_values(4) = p(4);
parameter_values(5) = p(5);
parameter_values(6) = p(6);
parameter_values(7) = p(7);
%parameter_values(8) = p(8);
%% calling to function solving ODE's

89
options=odeset('InitialStep',1e-10,'RelTol',1e-10,'Refine',1);%,'NormControl','on');
% temp = parameter_values;
x0 = [Ctub1 Ce_bar Cc Cm CcBc]; % mass/volume aka concentration input
calculated based off real experimental values (uM)
% calling to ode
[tfinal,xfinal] = ode45(@rhodamine6GSolver_single_pass_param_est_v3, ttdata,
x0, options, parameter_values);
Out = xfinal(:,2);
E.5 rhodamine6GSolver_single_pass_param_est_v3.m

function [ x_dot ] = rhodamine6GSolver_single_pass_param_est_v3(ttdata,x,
parameters)
global deltap F tt deltam_un
% define parameters
Ve = 0.85; %Physical lung vascular volume = 1 ml
Vc = 1.0; %0.67; %Physical lung tissue volume = 1 ml
Vm = 0.02*Vc; %Physical lung mitochondrial volume = 0.01*Vc (ml)
Vtub = 4; % measured Physical tubing volume (ml)
alpha = 0.0374158; %ZF/RT where Z is the valency of the ions (Na+, Ca2+, and
Cl-), F is Faraday’s constant ...
...(9.684 x 104 C/ mol), R is the gas constant (8.135 J/K*mol), and T is the
absolute temperature in K (273 + temp in Celcius). (mV-1)
Be = 0.5; %[BSA] Total vascular protein (BSA) concentration (uM)
kd1 = 0.32; %0.306430;%15; %k-1/k1 %Dissociation equilibrium constant for
dye-protein binding in the vascular region (umol-1*min-1)
%ps1 = 63.551726;
%%%%%%%%%%%%%%%%%
ps2
= parameters(1);
k2_bar
= parameters(2);
kminus2 = parameters(3);
kd3
= parameters(4);
deltam
= parameters(5);
%deltam_un = parameters(6);
vmaxkm
= parameters(6);
ps1
= parameters(7);
% calculate the apparent volumes
V3 = Vm*(1+(1/kd3)); %Apparent mitochondrial volume (ml)
%create vector of zeros

90
x_dot = zeros(5,1);
% get last time point from data gathered
time = tt(end);
% varying Cin based off phase and deltam
if ttdata >= 0 && ttdata <= (time-9.6) % phase 1... loading phase
Cin = 0.25;
elseif ttdata > (time-9.6) && ttdata <= (time-6.6) % phase 2... wash phase
Cin = 0;
elseif ttdata > (time-6.6) % phase 3... uncoupler phase
Cin = 0;
deltam = deltam_un; %Mitochondrial membrane potential (mV)
end
% Free concentration of r6g within the vascular region
Ce = (x(2)/(1+(Be)/(kd1))); %units = nmol/mL or umol/L
% calculate flux values
J1 = ((alpha*ps1*deltap)/(exp(alpha*deltap)-1))*(exp(alpha*deltap)*Ce-x(3));
%Dye flux across plasma membrane (nmol/min)
J2 = ((alpha*ps2*deltam)/(exp(alpha*deltam)-1))*(exp(alpha*deltam)*x(3)-x(4));
%Dye flux across inner mitochondrial membrane (nmol/min)
% ODE's - do differential computations here
x_dot(1,1) = (1.0/(Vtub))*F*(Cin-x(1)); % tubing region
x_dot(2,1) = (1/Ve)*(-J1+vmaxkm*x(3)+F*(x(1)-x(2))); % extracellular/vascular
region units = nmol/mL*min
x_dot(3,1) = kminus2*x(5)-k2_bar*x(3)+(1/Vc)*(J1-J2-vmaxkm*x(3)); %
cytoplasm region free
x_dot(4,1) = (1/V3)*(J2); % mitochondrial region units = nmol/mL*min
x_dot(5,1) = k2_bar*x(3)-kminus2*x(5); % cytoplasm region bound
end

